Explore every episode of the podcast STAT Stitch Deep Dive Podcast Beyond The Bedside
Dive into the complete episode list for STAT Stitch Deep Dive Podcast Beyond The Bedside . Each episode is cataloged with detailed descriptions, making it easy to find and explore specific topics. Keep track of all episodes from your favorite podcast and never miss a moment of insightful content.
Rows per page:
50
1–50 of 295
Title
Pub. Date
Duration
CC PHARM [RSI] | Vecuronium
25 Aug 2026
00:34:58
Vecuronium is an intermediate-acting, nondepolarizing neuromuscular blocking agent used for skeletal muscle relaxation during surgery, mechanical ventilation, and endotracheal intubation, including rapid-sequence intubation (RSI).
1. Critical Safety & Boxed Warning (The Vital 20%)
Respiratory Paralysis: Causes respiratory paralysis (potentially fatal). Administer only by experienced clinicians in settings with immediate intubation, ventilation, oxygen, and reversal agents.
Induction Prerequisite: To prevent extreme distress, vecuronium must only be administered after unconsciousness is induced with adequate amnesia, sedation, and analgesia.
Storage Warning: Due to risk of fatal accidental administration, store vials with cap/ferrule intact and separated from other drugs to prevent selection errors.
2. Mechanism of Action & Pharmacokinetics
Mechanism: Competes with acetylcholine (ACh) for receptors at the motor end-plate. Paralysis progresses predictably: fine muscles (eyes, face, neck) first, then limbs, chest, abdomen, and lastly the diaphragm. Recovery occurs in reverse order.
Onset & Duration: IV administration acts within 1 minute, peaks at 3 to 5 minutes, and lasts 25 to 40 minutes.
Metabolism & Elimination: 60% to 80% protein-bound. Active 3-desacetyl metabolite has 50% to 70% potency of parent compound. Elimination half-life: 65 mins (infants), 41 mins (children), and 65 to 75 mins (adults).
3. Core Clinical Dosing
Rapid-Sequence Intubation (RSI):
Adults:0.1-0.2 mg/kg IV (onset 2-4 mins).
Pediatrics (7 weeks to 17 years):0.15-0.2 mg/kg IV (onset 2.5-3 mins).
Neonates (<7 weeks):0.1 mg/kg IV (onset 2.5-3 mins).
Mechanical Ventilation & Surgery:
Adults:0.08-0.1 mg/kg initial IV bolus, then 0.01-0.015 mg/kg every 12-15 mins as needed, or continuous infusion of 0.8-1.7 mcg/kg/min.
Defasciculation:0.01 mg/kg IV given 1-3 mins before succinylcholine in adults. Rare in pediatrics.
4. Reconstitution & Stability
Reconstitution: Add 10 or 20 mL of Bacteriostatic Water to 10 or 20 mg vials (1 mg/mL). For neonates, use Sterile Water to avoid benzyl alcohol toxicity.
Storage: Bacteriostatic water reconstitution lasts 5 days (room temp/refrigerated); Sterile Water is single-use and discarded within 24 hours. Do not mix with alkaline solutions.
5. Monitoring & Adverse Effects
Monitoring: Use a peripheral nerve stimulator to monitor response (target: 1 to 2 twitches).
Adverse Reactions: Major risks include bronchospasm, anaphylaxis, acute myopathy, prolonged paralysis, tachycardia, and hypotension. Minimal histamine release occurs.
📊 I can generate a quick reference dosing card or a cheat sheet comparing these pediatric vs. adult infusion rates for your clinical review.
NURSE | Know Your Specialty
25 Aug 2026
00:10:34
pick your specialty that you want to get into, learn the certs you need for them and go for it.
CC Pharm [RSI] | Succinylcholine
25 Aug 2026
00:26:31
Succinylcholine is a short-acting, depolarizing neuromuscular blocking agent (NMBA) used as an adjunct to general anesthesia to facilitate tracheal intubation and provide skeletal muscle relaxation. Applying the 80/20 rule, the core clinical essence of succinylcholine centers on its rapid mechanism, critical safety warnings, and precise dosing.
1. Core Mechanism & Pharmacokinetics (The "20%" Driving Action)
Mechanism: Succinylcholine competes with acetylcholine (ACh) at cholinergic receptors on the motor end-plate, depolarizing the membrane. Resistant to acetylcholinesterase, it remains bound to inhibit repolarization, causing transient muscle fasciculations followed by flaccid paralysis.
Paralysis Order: Affects facial and glottis muscles first, then intercostals, diaphragm, and other skeletal muscles. Recovery occurs in the reverse order.
Pharmacokinetics: Highly ionized with low lipid solubility, it distributes rapidly in extracellular space. It is hydrolyzed by plasma cholinesterase to inactive metabolites.
Prolonged Blockade: Decreased plasma cholinesterase activity—due to genetics, liver/renal dysfunction, pregnancy, burns, or drugs (e.g., oral contraceptives)—prolongs neuromuscular blockade.
Severe Hyperkalemia: Contraindicated after the acute phase of major burns, multiple trauma, skeletal muscle denervation, or upper motor neuron injury. It can trigger severe hyperkalemia, peaking 7 to 10 days post-injury, causing cardiac arrest. Avoid if baseline potassium is > 5.5 mEq/L.
Pediatric Safety: Contraindicated in patients with skeletal muscle myopathy (e.g., Duchenne's). Reserve pediatric use for emergency intubation due to risks of rhabdomyolysis and sudden hyperkalemic cardiac arrest (often presenting as peaked T-waves).
Malignant Hyperthermia (MH): Contraindicated in patients with genetic susceptibility (RYR1 or CACNA1S variants). Inhalation anesthetics compound this risk. Continuous ETCO2 and temperature monitoring are vital for early recognition.
3. Key Clinical Dosing & Administration
Rapid-Sequence Intubation (RSI):
Adults: 1.5 mg/kg IV (onset ~1 min).
Pediatrics (2-17 years): 1 to 1.5 mg/kg IV.
Infants & Neonates: 2 mg/kg IV.
Non-Emergent Intubation:
Adults: 0.6 mg/kg IV (range: 0.3 to 1.1 mg/kg).
Intramuscular (IM) Backup: Used if IV access is unavailable. Adults: 3 to 4 mg/kg (Max: 150 mg); Infants/Children: 4 to 5 mg/kg IM. Onset is 2 to 5 minutes.
Incompatibilities: Succinylcholine is acidic (pH 3 to 4.5); do not mix with alkaline solutions (pH > 8.5).
CC Pharm [RSI] | Etomidate
25 Aug 2026
00:28:55
Etomidate (Amidate) is a short-acting sedative-hypnotic intravenous general anesthetic. Applying the 80/20 rule, this summary focuses on the core 20% of clinical details that deliver 80% of the practical knowledge needed for its safe administration:
1. Clinical Pharmacology & Mechanism
Mechanism: Facilitates GABAminergic neurotransmission by increasing available GABA receptors, possibly by displacing endogenous inhibitors of GABA binding.
Cerebral Effects: Reduces cerebral blood flow by 20% to 30%, lowers intracranial pressure (ICP) moderately for several minutes, and decreases intraocular pressure.
Adrenal Impact: Inhibits steroidogenesis by blocking 11-beta-hydroxylation in the adrenal cortex, reducing plasma cortisol and aldosterone. This prevents its long-term use for ICU sedation.
Pharmacokinetics: Onset of action is 0.5 to 1 minute, with a hypnotic duration of 3 to 5 minutes at a standard 0.3 mg/kg dose. It is 76% protein-bound, rapidly metabolized in the liver via ester hydrolysis, and has a 75-minute half-life.
2. Primary Indications & Dosing
Anesthesia Induction:0.2 to 0.6 mg/kg IV over 30 to 60 seconds (usual dose: 0.3 mg/kg).
Subpotent Anesthetic Supplementation:0.2 to 0.6 mg/kg IV over 30 to 60 seconds (usually lower than induction doses).
Rapid-Sequence Intubation (RSI):0.15 mg/kg IV for unstable patients and 0.3 mg/kg IV for stable patients. It is highly useful in head trauma, multiple traumas, cardiovascular disease, and non-sepsis hypotension as it lowers ICP with minimal systemic blood pressure impact.
Procedural Sedation:0.1 to 0.3 mg/kg IV (max: 20 mg/dose) over 30 to 60 seconds. Note: Etomidate does not have analgesic properties.
Severe Hypercortisolism (Cushing's Syndrome):0.04 to 0.1 mg/kg/hour IV infusion for ICU patients, or 0.025 mg/kg/hour for non-ICU patients.
3. Safety, Risks & Administration
Administration: IV use only by trained personnel. Do not use for prolonged infusion.
Adverse Reactions: Most common are myoclonia (74% incidence) and injection site reactions (1.2% to 42%). Severe reactions include apnea, laryngospasm, bradycardia, arrhythmia exacerbation, and anaphylactoid reactions. Adrenocortical insufficiency and hypoaldosteronism are potential delayed risks.
Special Populations:
Renal/Hepatic Impairment: Lower doses may be needed, particularly with cirrhosis.
Lactation: Caution is advised. In post-Cesarean mothers, etomidate is excreted in colostrum but is undetectable by 4 hours; nursing is safe once the mother is awake and alert.
CC Pharm [RSI] | Rocuronium
25 Aug 2026
00:26:45
The 80%: Core Clinical Guidelines & Actionable Insights
Role: Intermediate-acting, nondepolarizing neuromuscular blocker (NMBA) for routine/RSI intubation, surgery, or mechanical ventilation.
Mechanism: Competes with acetylcholine at motor end-plates. Paralysis moves from fine muscles (face/neck) to limbs, chest, abdomen, and diaphragm; recovery is in reverse. A vecuronium analog with 10–15% potency, it was developed to match succinylcholine's onset. Minimal histamine release/ganglion blockade makes bronchospasm, hypotension, or heart rate shifts rare.
Crucial Administration:
Rules: Give only after unconsciousness is induced with sedation, analgesia, and amnesia. Ventilatory support is mandatory. Do not mix with alkaline solutions (e.g., thiopental) due to acidic pH.
Monitoring/Route: Direct IV over 5–10s; monitor with nerve stimulators (target 1–2 twitches). Infusions dilute up to 5 mg/mL (or 10 mg/mL undiluted). IM use is non-FDA-approved and discouraged (slow/inconsistent).
The 20%: Pharmacokinetics, Special Populations, & Risks
Pharmacokinetics: Extracellular distribution (not fat), ~30% protein bound. Tissue redistribution accounts for 80% of initial dose; maintenance infusion falls to ~20% of initial rate in 4–8 hours as tissues fill. CYP3A4 metabolizes it to an active form with 1/20th potency. Half-life: neonates (1.1h), older children (0.7–0.8h), adults (1.4–2.4h). Bolus duration: 22–67 min.
Lactation: Poor lipid solubility and oral absorption make infant exposure unlikely (breastfeeding can resume 90m–5h post-anesthesia).
Adverse & Storage: Severe risks: bronchospasm, anaphylaxis, angioedema, malignant hyperthermia, acute myopathy, thrombosis. Shortage update: FDA allows emergency extended vial use up to 2h at room temp or 4h refrigerated.
CC Pharm | Ketamine POSSIBLE [RSI]
25 Aug 2026
00:22:04
Expected Action & Physiology
Ketamine is a nonbarbiturate phencyclidine derivative that acts as an NMDA receptor antagonist, blocking glutamate to selectively interrupt thalamoneocortical pathways while stimulating the limbic system. This induces "dissociative anesthesia" where the patient is unresponsive to pain, but eyes remain open with intact corneal, light, and airway reflexes.
It stimulates the sympathetic system, causing bronchodilation (ideal for asthma/bronchospasm), tachycardia, and hypertension. Direct negative inotropic effects can predominate in critically ill or catecholamine-depleted patients, causing hypotension. Cholinergic activation causes hypersalivation and elevated ICP/IOP.
Therapeutic Uses & Dosing
Uses: Anesthesia induction/maintenance, procedural sedation, RSI (preferred in shock/bronchospasm), plus off-label status asthmaticus, pain, and delirium/agitation.
IV: Onset: 30–60s (rapid brain circulation); duration: 5–10 min. Dilute 100 mg/mL push and infuse slowly over ≥60s (max 0.5 mg/kg/min) to prevent respiratory depression.
IM: Onset: 3–5 min; duration: 12–30 min. No dilution.
Other: Intranasal (bioavailability 35–50%, onset 5–20 min). Oral/Rectal are less predictable due to high first-pass metabolism.
Pharmacokinetics & Metabolism
Highly lipid-soluble with low protein binding (12%), it rapidly distributes to the brain. It is metabolized by CYP3A4 into norketamine (active metabolite, one-third potency of ketamine). Half-life is 2–3 hours. Chronic use induces hepatic enzymes. No renal/hepatic dose adjustments are required.
Complications & Nursing Pearls
Emergence Reactions: Hallucinations, delirium, or nightmares occur in ~12% of patients. Intervention: Minimize verbal, tactile, and visual stimulation during recovery. Severe reactions can be terminated with benzodiazepines or barbiturates.
Tonic-Clonic Movements: Purposeless movements can occur but do not indicate a light plane or need for more ketamine.
Severe Risks: Laryngospasm, apnea, cardiac arrest, and increased ICP/IOP. Contraindication: Do not use as sole agent for procedures involving the larynx/pharynx or requiring muscle relaxation.
Administration: Give on empty stomach to prevent vomiting/aspiration. Give an anticholinergic beforehand to limit oral secretions.
1. Action & Class:Benzothiazepine Class IV anti-arrhythmic/anti-anginal. Inhibits calcium influx across myocardial and vascular smooth muscle membranes. This slows AV conduction (prolonging the PR interval), decreases heart rate, and dilates coronary and systemic arteries, reducing afterload and blood pressure. It has fewer negative inotropic effects than verapamil.
2. Therapeutic Uses:Hypertension, stable/variant (Prinzmetal's) angina, and ventricular rate control in atrial fibrillation (AFib), atrial flutter, or PSVT.
3. Administration & Dosages:
IV Push: Undiluted, over 2 minutes (0.25 mg/kg bolus; can repeat at 0.35 mg/kg in 15 minutes if needed).
Continuous IV:1 mg/mL dilution, starting at 10 mg/hour; titrate to a maximum of 15 mg/hour (duration >24 hours is not recommended).
Oral: IR tablets (30–90 mg, 3–4 times daily). ER formulations (12- or 24-hour) range 120–360 mg/day (maximum 360–540 mg/day depending on formulation). Do not crush or chew ER formulations.
4. Complications & Adverse Effects:
Severe:Bradycardia, high-degree AV block, asystole, heart failure, and life-threatening dermatologic reactions like Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN).
Common:Peripheral edema (up to 15%), hypotension (4.3%), constipation (3.6%), headache (8.9%), and dizziness (10%).
5. Contraindications & Interactions:
Contraindications: Severe heart failure, sick sinus syndrome, 2nd/3rd-degree AV block (without a functioning pacemaker), cardiogenic shock risk, or atrial arrhythmias presenting with pre-excitation (e.g., Wolff-Parkinson-White).
Interactions:CYP3A4 substrate and inhibitor; can significantly raise levels of co-administered CYP3A4 substrates. Avoid/limit grapefruit juice (increases drug half-life). Concurrent beta-blockers severely compound the risk of AV block.
6. Nursing Interventions:
Monitoring: Monitor ECG (PR interval) and blood pressure/heart rate continuously during IV therapy.
Hold Parameters:Hold the dose and immediately notify the provider for severe bradycardia, new-onset heart block, or profound hypotension.
Organ Function:Reduce dosage in hepatic impairment (increases half-life and bioavailability); no renal adjustments are required.
7. Client Education:
Never split, crush, or chew ER formulations. However, Tiazac capsules can be opened and sprinkled on cool, non-hot applesauce.
Change positions slowly to prevent orthostatic hypotension and syncope.
Report severe rashes, swelling in lower extremities, or extreme fatigue immediately.
Mechanism: Enhances GABA-A receptors, increasing GABA affinity and opening chloride channels. This hyperpolarizes cell membranes, preventing excitation. Has twice the receptor affinity of diazepam.
Pharmacokinetics: Metabolized by CYP3A4 to active, equipotent alpha-hydroxymidazolam. 97% protein-bound. Excreted via urine.
IV: Onset 1.5–5m, duration 30–45m. Tissue accumulation in long infusions delays awakening.
Buccal/Rectal (Off-label): Onset is 10–30m; duration 40–90m.
Black Box Warning & Complications
Boxed Warnings: Requires specialized care setting, experienced clinician, and continuous cardio-respiratory monitoring. Profound risk of respiratory depression, apnea, arrest, and hypoxic encephalopathy/death. Coadministration with opioids or other CNS depressants severely increases risks of profound sedation, respiratory depression, coma, or death.
Monitoring: Continuously monitor respiratory effort and oxygenation (pulse oximetry) to detect hypoventilation or apnea early.
Slow IV Push: Administer over ≥2 minutes; wait ≥2 minutes to assess effects before redosing. Avoid rapid push in neonates (risk of severe hypotension, hypoventilation, seizures).
Antidote:Flumazenil must be immediately available to reverse respiratory depression. Note: Flumazenil can precipitate life-threatening seizures in chronic benzodiazepine users.
Gradual Taper: Do not abruptly stop after continuous use (>1–2 weeks); taper gradually to avoid acute withdrawal (seizures, status epilepticus).
Pediatric & Neonatal Safety: Preterm neonates have significantly slower clearance. Standard infusions are not recommended for preterm neonates <32 weeks due to adverse neurological risks. Avoid benzyl alcohol-containing injectables in neonates to prevent fatal "gasping syndrome".
Renal/Hepatic: Half-life is prolonged in renal impairment; pediatric doses must be reduced by 25% (GFR 10–29) or 50% (GFR <10). Reduced clearance occurs in hepatic impairment.
Why Choose This Drug? Preferred for rapid-onset, short-duration procedural sedation, amnesia, and acute seizure control (drug of choice for emergent IM seizure therapy)
CC Pharm | Nitroprusside
19 Aug 2026
00:19:11
Sodium nitroprusside is an ultra-potent, direct-acting peripheral vasodilator characterized by rapid hemodynamic action and highly toxic metabolites. This 80/20 summary distills its essential clinical, pharmacological, and nursing guidelines:
1. Mechanism & Hemodynamic Effects
Mechanism: Direct action on arterial and venous smooth muscle; myocardial contractility is unaffected.
Hypertension: Reduces afterload and causes venous pooling, decreasing arteriolar resistance.
Heart Failure: Improves left ventricular performance, increasing cardiac index, cardiac output, and stroke volume while slowing heart rate.
2. Dosing & Clinical Administration
Onset & Duration: Rapid onset (1-2 mins); effects persist for 1-10 mins after discontinuation.
Titration: Confirm drug effect for 5 minutes before titrating to a higher dose.
Dosing (Adults):
Hypertensive Emergency: Start 0.3-0.5 mcg/kg/min; titrate by 0.5 mcg/kg/min every 5 mins. Max: 10 mcg/kg/min for 10 mins.
Acute Heart Failure: Start 0.1-0.3 mcg/kg/min. Max: 10 mcg/kg/min (doses >400 mcg/min have no added benefit).
Mitral Regurgitation: Start 15 mcg/min, titrate every 2 mins to reduce mean arterial pressure by 10-20 mmHg.
Preparation & Administration:
Dilute 50 mg in 250–1000 mL of 5% Dextrose (D5W). Never give direct IV injection.
Solution is clear, colorless to red/brown; discard if blue, green, or bright red.
Protect from light during administration with an opaque sleeve.
Doses >2 mcg/kg/min exceed normal clearance. Buffering is exceeded in <1 hour at the max 10 mcg/kg/min rate.
Action: Discontinue and consider sodium nitrite and sodium thiosulfate.
Thiocyanate Toxicity: Cyanide converts to thiocyanate via mitochondrial rhodanase (renal half-life: 3 days).
Life-threatening at 200 mg/L. Monitor plasma levels if cumulative doses exceed 7 mg/kg/day.
Organ Impairment Risk:
Hepatic disease: High susceptibility to cyanide toxicity.
Renal Impairment: eGFR <30: limit mean infusion to <3 mcg/kg/min (Anuria: limit to 1 mcg/kg/min).
4. Nursing Interventions
Monitoring: Mandatory continuous blood pressure monitoring, preferably via an intraarterial pressure sensor. Monitor urine output in heart failure.
Safety: Use a volumetric infusion pump. Watch for hypotension, methemoglobinemia, bradycardia, or metabolic acidosis.
CC Pharm | Dobutamine
19 Aug 2026
00:21:49
Dobutamine is a direct-acting parenteral sympathomimetic inotrope. It primarily acts as an agonist at beta1-adrenergic receptors (with minor beta2 and alpha1 stimulatory effects) to increase myocardial contractility, stroke volume, and cardiac output. Unlike dopamine, it does not stimulate dopaminergic receptors or release norepinephrine. It has comparatively mild chronotropic, hypertensive, arrhythmogenic, and vasodilative effects, and minimally affects pulmonary vascular resistance.
Primary Indications & Clinical Dosing:
Low Output States: Used for short-term treatment of cardiac decompensation due to depressed contractility from organic heart disease, cardiac surgery, congestive heart failure, cardiogenic shock, or septic shock.
Continuous IV Dosage: Initiate adults, children, and neonates at 0.5 to 1 mcg/kg/min, titrating to a usual dose of 2 to 20 mcg/kg/min based on response. Rates >20 mcg/kg/min may cause tachycardia or ectopy; 40 mcg/kg/min is rarely required.
Diagnostics: Used in dobutamine stress echocardiography starting at 5 mcg/kg/min, titrating up to 40 mcg/kg/min.
Special Populations: No dose adjustments are needed for renal or hepatic impairment.
Critical Administration Rules:
Dilution & Infusion: Must be diluted before use (maximum concentration 5,000 mcg/mL; standard adult concentration is 4,000 mcg/mL). Infuse using a controlled device, preferably into a large vein.
Incompatibilities: Incompatible with sodium bicarbonate or strong alkaline solutions. Do not infuse dextrose-containing dobutamine through the same line as blood due to risk of pseudoagglutination/hemolysis.
Physical Stability: Premixed bags in 5% Dextrose may turn pink over time due to slight oxidation, which does not impact potency.
Intraosseous (IO): Not FDA-approved, but the same dose can be given via IO route during CPR if IV access is unfeasible.
Pharmacokinetics & Safety Profile:
Rapid Action: Infused intravenously, it has an onset of 2 minutes and a half-life of ~2 minutes.
Severe Adverse Reactions: Can cause ventricular tachycardia, arrhythmia exacerbation, pulmonary edema, skin necrosis, and anaphylactoid reactions.
Moderate Reactions: Includes hypertension, angina, palpitations, dyspnea, and premature ventricular contractions. Dosage titration must be guided closely by systemic blood pressure, heart rate, urine flow, and ectopic activity.
CC Pharm | Milrinone
19 Aug 2026
00:36:08
Core Profile & MechanismMilrinone is a parenteral positive inotrope and vasodilator with selective phosphodiesterase III (PDE3) inhibitor activity. By preventing cyclic adenosine monophosphate (cAMP) breakdown in cardiac and vascular muscle cells, it increases myocardial contractility, causes vasodilation, and improves diastolic relaxation (lusitropy). This dual action reduces preload, afterload, and systemic vascular resistance with little to no chronotropic activity. Therapeutic effects occur at plasma levels of 100 to 300 ng/mL.
Primary Indications Milrinone is used for the short-term treatment of acute heart failure and other low cardiac output states like cardiogenic shock or post-cardiac surgery low cardiac output syndrome (LCOS). It can provide long-term palliative support in stage D heart failure patients awaiting transplant or mechanical circulatory support. Off-label uses include pediatric septic shock or postresuscitation stabilization, cerebral vasospasm after aneurysmal subarachnoid hemorrhage, and persistent pulmonary hypertension of the newborn (PPHN) with poor nitric oxide response.
Dosing & Administration
Adult HF Dosing: A 50 mcg/kg IV loading dose over 10–60 minutes (though heart failure guidelines do not recommend a bolus), followed by 0.125 to 0.75 mcg/kg/minute continuous infusion.
Renal Adjustments: Elimination is primarily renal (83% excreted unchanged in urine, half-life of 2.4 hours). For CrCl ≤ 50 mL/min, the adult continuous infusion rate must be adjusted down sequentially from 0.43 mcg/kg/min (CrCl 41–50) down to 0.2 mcg/kg/min (CrCl ≤ 5). Pediatric rates also require reductions for CrCl < 50 mL/min.
Administration Safety: Standard infusion is 200 mcg/mL, diluted in 0.45% or 0.9% NaCl or 5% Dextrose, run via a controlled device. It is not FDA-approved for intraosseous use, but the same doses can be given IO if IV access is unavailable.
Critical Safety & Adverse Reactions
Incompatibilities:Milrinone must never be co-administered with furosemide, as precipitation occurs immediately in the same line. It also cannot be given simultaneously with blood.
Arrhythmias & Monitoring:Continuous ECG monitoring is mandatory. Milrinone carries a substantial risk of serious ventricular arrhythmias (VT up to 12%, VF 0.2%), atrial flutter/fibrillation (up to 8%), supraventricular tachycardia, and premature ventricular contractions.
Hypotension & Other Risks: Hypotension occurs in 2.9% to 10.7% of patients. To reduce this risk, clinicians often avoid the loading dose in septic shock and neonatal PPHN. Thrombocytopenia is a delayed reaction occurring in up to 58% of patients.
CC Pharm | Norepinephrine
19 Aug 2026
00:23:14
Norepinephrine (Levophed) 80/20 Summary
Action & MOA: Direct α-agonist causing potent vasoconstriction. Modest β1 activity triggers cardiac stimulation at lower doses; vasoconstriction dominates at higher doses. Elevated SVR triggers reflex vagal bradycardia (slowing HR). Coronary flow increases without raising myocardial oxygen demand.
Uses: First-line for septic shock, sepsis, acute hypotension, cardiogenic shock. Alternative in hepatorenal syndrome (with albumin).
Complications:Tissue necrosis (extravasation), bradycardia, lactic acidosis, pulmonary edema, hypertension, and local hypoxia.
Administration & Dilution:
Dilution: Standard: 4mg in 1,000mL. Preferred: D5W/D5NS (dextrose protects against oxidation). Saline alone stable up to 16mcg/mL, though FDA discourages. Adult standard: 16, 32, 128mcg/mL.
Incompatibility:Do not mix with alkaline solutions (e.g., bicarb). Reject if pinkish/discolored or has precipitate.
Route:Large vein infusion; transition to central line ASAP. Avoid leg veins in elderly.
Monitoring:BP every 2 mins initially, then every 5 mins. Check site frequently for free flow/extravasation.
Weaning:Reduce rate gradually; avoid abrupt withdrawal to prevent rebound hypotension.
Extravasation Antidote: Infiltrate ASAP (within 12h) with phentolamine 5-10mg in 10-15mL NS.
Why Choose It? Preferred in septic shock; raises MAP/SVR with less tachycardia than dopamine, sparing oxygen demand.
Final 80/20 Review
The 20% to Absolutely Know:
Hypovolemia First: Correct fluid deficit before starting norepinephrine.
Central Line Priority: Transition to central line ASAP to mitigate necrosis risk.
Phentolamine for Extravasation: Immediate local infiltration reverses ischemia.
Dextrose Over Saline: Dextrose-containing diluents prevent oxidation.
Incompatible with Bicarb: Inactivated in alkaline solutions.
If I Remember Nothing Else: Norepinephrine is the first-line vasopressor for septic shock. With a <30s onset and 2.4m half-life, it requires continuous infusion, BP checks every 2–5 mins, and gradual weaning. Monitor the IV site continuously; treat extravasation with immediate phentolamine infiltration to prevent necrosis.
CC Pharm | Precedex
19 Aug 2026
00:24:15
Pharmacological Action & Use: Dexmedetomidine (Precedex) is a selective, centrally-acting alpha-2 adrenergic receptor agonist. Presynaptic activation inhibits norepinephrine release and pain signals; postsynaptic CNS activation inhibits sympathetic activity, decreasing heart rate and blood pressure. This produces arousable sedation, anxiolysis, and mild analgesia without significant effects on respiratory drive. It is indicated for ICU ventilator sedation, procedural sedation, and acute psychiatric agitation (sublingual film).
Why Choose It: Unlike benzodiazepines or propofol, it sedates without causing respiratory depression, making it ideal for weaning mechanically ventilated patients. It is 8 times more selective for alpha-2 receptors than clonidine.
Complications & Safety Concerns: The most common adverse reactions are dose-related bradycardia and hypotension. Rapid IV administration can activate peripheral alpha-2 receptors, causing transient hypertension and reflex bradycardia. Other severe risks include ARDS, atrial fibrillation, and cardiac arrest.
Critical Administration Rules:
Intravenous: Standard ICU dilution is 4 mcg/mL. Never give via IV push. Infuse loading doses over 10 minutes; however, loading doses are frequently bypassed in practice to avoid severe bradycardia and hypotension. Run on a controlled device. Do not coadminister in the same catheter with blood, serum, or plasma.
Sublingual Film (Igalmi): Dissolves in 6–8 minutes. Administer only under direct medical supervision. Instruct the patient not to chew/swallow the film, and avoid food or drink for 15 minutes after sublingual (or 1 hour after buccal) administration. Peak reductions in HR and BP occur 2 hours post-dose; patients must remain seated/lying down and be assessed for orthostatic hypotension before ambulating.
When to Hold Sublingual Film: SBP < 90 mmHg, DBP < 60 mmHg, HR < 60 bpm, or a postural drop of SBP ≥ 20 mmHg / DBP ≥ 10 mmHg.
Hepatic Impairment: Requires initial IV dose reductions and strict sublingual dose limits (e.g., 60–120 mcg initial dose based on Child-Pugh severity) due to liver metabolism.
Clinical Mnemonic & Scenario:
Mnemonic: PREcedex = Prevents Respiratory Embarrassment (spares the respiratory drive).
Scenario: A ventilated ICU patient is undergoing a spontaneous breathing trial but becomes highly agitated. Precedex is initiated because it calms the patient and maintains arousability without suppressing their respiratory drive.
THE 20% TO REMEMBER:
Arousable sedation with zero respiratory depression.
Bypass IV loading doses to prevent severe bradycardia and hypotension.
Assess vitals 2 hours after sublingual dose; hold if HR < 60 or BP < 90/60.
No food/water for 15 mins (sublingual) / 1 hour (buccal).
IV/IM: Peak IV analgesia in minutes. Inject slowly over 1–3 min; rapid injection can cause apnea or chest wall rigidity.
Transdermal Patch: Onset 12–24h; changed every 72h. Epidermal depot slowly absorbs. Critical: Avoid external heat (pads, saunas, fevers >104°F); heat increases absorption by 120%, risking fatal overdose. Clip, do not shave, hair. Fold adhesive inward and flush.
Transmucosal (Actiq, Fentora, Onsolis, Abstral, Subsys, Lazanda): For breakthrough pain in opioid-tolerant patients ONLY. Follow specific directions (e.g., suck Actiq lozenge, do not chew; do not suck/chew/swallow Abstral). Dry hands. Flush unneeded forms or use specific pouches.
Ionsys: Iontophoretic system (hospital only). Delivers dose via 10-min current. Wear gloves; never touch hydrogels. 4. High-Yield Contraindications & Precautions:
Respiratory: Contraindicated in severe respiratory depression or acute/severe asthma in unmonitored settings.
Renal/Hepatic: Reduce transdermal dose by 50% in mild-to-moderate impairment; avoid in severe.
Pregnancy: Prolonged maternal use causes Neonatal Opioid Withdrawal Syndrome (NOWS); monitor newborn for tremors, high-pitched cry, irritability, vomiting, and diarrhea. 5. Black Box Warnings & Toxicity:
Addiction, abuse, misuse, and fatal respiratory depression.
Accidental Exposure: Ingestion of patches is fatal, especially in children. Wash hands after handling.
Reversal: Keep Naloxone (Narcan) and resuscitative equipment readily available. 6. Key Drug Interactions:
CYP3A4 Inhibitors: Prevent fentanyl metabolism, increasing levels and risk of fatal respiratory depression.
CNS Depressants: Cause profound sedation, respiratory depression, coma, and death. 7. Nursing Interventions:
Assess: Prioritize respiratory rate, depth, and pupil size (miosis). Monitor pain and sedation.
Monitor: Use continuous pulse oximetry for infusions. Monitor patch adhesion, especially in pediatric or cognitively impaired patients.
Hold & Notify: If RR < 12/min, shallow breathing, or excessive sedation.
CC | Lido c/ & Lido c/ out
18 Aug 2026
00:08:03
this episode talks about the trauma uses of Lidocaine c/ Epi or Lidocaine c/out Epi. its commonly known as Lido c/ or Lido c/ out.
THIS IS NOT THE SAME MED YOU GIVE IN THE ACLS ALGO
CC | PRIMER Burns
13 Aug 2026
00:21:34
Burn Classification & TBSA Assessment Burn severity depends on depth, extent (TBSA), location, and patient risk factors. Depth is classified as partial-thickness (epidermal/dermal; painful, red, blistered) or full-thickness (dermal destruction, painless, leathery eschar, visible thrombosed vessels). TBSA is estimated using the Rule of Nines for adults or the Lund-Browder chart for children. Referral to a burn center is indicated for partial-thickness burns >10% TBSA, chemical/electrical burns, inhalation injury, or burns of the face, hands, feet, genitalia, perineum, or joints. Face, neck, and circumferential torso burns threaten ventilation. Circumferential limb burns impair perfusion, requiring escharotomy.
Emergent Phase Pathophysiology & Resuscitation The emergent phase (first 72 hours) prioritizes burn shock and gas exchange. Loss of capillary seal triggers a massive fluid shift from the intravascular to the interstitial space (third spacing), causing severe hypovolemia, hemoconcentration, high blood viscosity, and increased peripheral resistance. Damaged cells release potassium (hyperkalemia), and sodium moves into the interstitium (hyponatremia). Inhalation injuries (carbon monoxide, above/below glottis) cause mucosal edema, obstruction, and pneumonia (the leading cause of death). Myoglobinuria (from electrical muscle damage) can block renal tubules, causing acute kidney injury (AKI). Priority care includes early intubation, 100% humidified O2, and resuscitation. The ABA formula dictates 2–4 mL Lactated Ringer's per kg per % TBSA in the first 24 hours (half in the first 8 hours). Target clinical parameters are MAP >65 mmHg, HR <120 bpm, and adult urine output of 0.5–1 mL/kg/hr (75–100 mL/hr for electrical burns).
Acute, Rehabilitative & Psychosocial Care The acute phase begins with diuresis and ends when wounds are nearly healed. Sepsis, often from gram-negative bacteria or Candida, is a leading cause of death during this immunosuppressed period. Stress-induced hypermetabolism causes protein catabolism and transient hyperglycemia, requiring early enteral nutrition and insulin. Excision and grafting (autograft, CEA, or Integra) are vital for full-thickness wounds. Pain is managed with continuous IV opioids, procedural breakthrough doses, and anxiolytics. Continuous physical therapy and splinting prevent contractures. In the rehabilitation phase, hypertrophic scars are minimized using custom-fitted pressure garments worn up to 23 hours daily for 12–18 months. Hydration and antihistamines help relieve severe itching. Older adults face higher mortality due to thinner skin, delayed healing, and co-morbidities. Support groups and psychiatric interventions address emotional needs, body image changes, and PTSD.
CC | Burns
13 Aug 2026
00:45:46
Burn Classification & TBSA Assessment Burn severity depends on depth, extent (TBSA), location, and patient risk factors. Depth is classified as partial-thickness (epidermal/dermal; painful, red, blistered) or full-thickness (dermal destruction, painless, leathery eschar, visible thrombosed vessels). TBSA is estimated using the Rule of Nines for adults or the Lund-Browder chart for children. Referral to a burn center is indicated for partial-thickness burns >10% TBSA, chemical/electrical burns, inhalation injury, or burns of the face, hands, feet, genitalia, perineum, or joints. Face, neck, and circumferential torso burns threaten ventilation. Circumferential limb burns impair perfusion, requiring escharotomy.
Emergent Phase Pathophysiology & Resuscitation The emergent phase (first 72 hours) prioritizes burn shock and gas exchange. Loss of capillary seal triggers a massive fluid shift from the intravascular to the interstitial space (third spacing), causing severe hypovolemia, hemoconcentration, high blood viscosity, and increased peripheral resistance. Damaged cells release potassium (hyperkalemia), and sodium moves into the interstitium (hyponatremia). Inhalation injuries (carbon monoxide, above/below glottis) cause mucosal edema, obstruction, and pneumonia (the leading cause of death). Myoglobinuria (from electrical muscle damage) can block renal tubules, causing acute kidney injury (AKI). Priority care includes early intubation, 100% humidified O2, and resuscitation. The ABA formula dictates 2–4 mL Lactated Ringer's per kg per % TBSA in the first 24 hours (half in the first 8 hours). Target clinical parameters are MAP >65 mmHg, HR <120 bpm, and adult urine output of 0.5–1 mL/kg/hr (75–100 mL/hr for electrical burns).
Acute, Rehabilitative & Psychosocial Care The acute phase begins with diuresis and ends when wounds are nearly healed. Sepsis, often from gram-negative bacteria or Candida, is a leading cause of death during this immunosuppressed period. Stress-induced hypermetabolism causes protein catabolism and transient hyperglycemia, requiring early enteral nutrition and insulin. Excision and grafting (autograft, CEA, or Integra) are vital for full-thickness wounds. Pain is managed with continuous IV opioids, procedural breakthrough doses, and anxiolytics. Continuous physical therapy and splinting prevent contractures. In the rehabilitation phase, hypertrophic scars are minimized using custom-fitted pressure garments worn up to 23 hours daily for 12–18 months. Hydration and antihistamines help relieve severe itching. Older adults face higher mortality due to thinner skin, delayed healing, and co-morbidities. Support groups and psychiatric interventions address emotional needs, body image changes, and PTSD.
Core Concepts & Emergency Recognition A stroke is an emergency where cell death occurs due to ischemia (inadequate blood flow, 87% of cases) or hemorrhage (bleeding, 13%). Interruption of blood flow alters brain metabolism in 30 seconds, stops it in 2 minutes, and causes cell death in 5 minutes. The FAST protocol is critical for rapid recognition: Face drooping, Arm weakness/drift, Speech difficulties, and Time of symptom onset (critical for determining treatment eligibility).
Pathophysiology & Classification
Ischemic Stroke: Divided into Thrombotic (60% of cases; associated with hypertension, diabetes, and atherosclerosis; symptoms develop slowly/stepwise) and Embolic (clot from the heart, often due to atrial fibrillation, travels and occludes a cerebral artery; onset is sudden with severe deficits).
Hemorrhagic Stroke: Includes Intracerebral (bleeding into brain tissue, mostly caused by hypertension) and Subarachnoid (SAH) (bleeding into CSF-filled space, often from ruptured aneurysms). SAH can trigger severe vasospasms, peaking 6–10 days post-bleed.
Key Diagnostics & Triage Immediate noncontrast head CT or MRI is mandatory to rapidly differentiate ischemic from hemorrhage. The NIH Stroke Scale (NIHSS) (scores 0–42) is the primary clinical tool to document baseline severity and track neurologic changes.
Acute Interventions & Hemodynamic Targets
Ischemic: IV tPA must be given within 3 to 4.5 hours of symptom onset after screening out hemorrhage, active bleeding, or recent trauma. Endovascular therapy with stent retrievers is highly effective. Keep BP <185/110 mmHg before tPA, and <180/105 mmHg for 24 hours after. If ineligible for tPA, lower BP only if SBP >220 or DBP >120 mmHg.
Hemorrhagic: Anticoagulants and antiplatelets are strictly contraindicated. Manage hypertension to maintain SBP <160 mmHg. For SAH, administer the calcium channel blocker nimodipine to prevent vasospasm.
High-Priority Nursing ADPIE Actions
Airway & Aspiration: Keep the patient NPO until a formal swallowing screen is completed within 24 hours to prevent aspiration pneumonia.
ICP Management: Elevate the head of bed 30°, keep head/neck in midline, and avoid hip flexion to maximize venous drainage and reduce intracranial pressure.
Safety & Pattern Recognition: Left-brain stroke causes right hemiplegia, aphasia, slow/cautious behavior, and depression. Right-brain stroke causes left hemiplegia, spatial-perceptual neglect, and highly impulsive, safety-compromising behavior. Protect from injury and address one-sided neglect.
VTE Prophylaxis: Implement passive/active range of motion, sequential compression devices, and low-molecular-weight heparin.
CC | Stroke [CVA]
12 Aug 2026
01:03:15
Core Concepts & Emergency Recognition A stroke is an emergency where cell death occurs due to ischemia (inadequate blood flow, 87% of cases) or hemorrhage (bleeding, 13%). Interruption of blood flow alters brain metabolism in 30 seconds, stops it in 2 minutes, and causes cell death in 5 minutes. The FAST protocol is critical for rapid recognition: Face drooping, Arm weakness/drift, Speech difficulties, and Time of symptom onset (critical for determining treatment eligibility).
Pathophysiology & Classification
Ischemic Stroke: Divided into Thrombotic (60% of cases; associated with hypertension, diabetes, and atherosclerosis; symptoms develop slowly/stepwise) and Embolic (clot from the heart, often due to atrial fibrillation, travels and occludes a cerebral artery; onset is sudden with severe deficits).
Hemorrhagic Stroke: Includes Intracerebral (bleeding into brain tissue, mostly caused by hypertension) and Subarachnoid (SAH) (bleeding into CSF-filled space, often from ruptured aneurysms). SAH can trigger severe vasospasms, peaking 6–10 days post-bleed.
Key Diagnostics & Triage Immediate noncontrast head CT or MRI is mandatory to rapidly differentiate ischemic from hemorrhage. The NIH Stroke Scale (NIHSS) (scores 0–42) is the primary clinical tool to document baseline severity and track neurologic changes.
Acute Interventions & Hemodynamic Targets
Ischemic: IV tPA must be given within 3 to 4.5 hours of symptom onset after screening out hemorrhage, active bleeding, or recent trauma. Endovascular therapy with stent retrievers is highly effective. Keep BP <185/110 mmHg before tPA, and <180/105 mmHg for 24 hours after. If ineligible for tPA, lower BP only if SBP >220 or DBP >120 mmHg.
Hemorrhagic: Anticoagulants and antiplatelets are strictly contraindicated. Manage hypertension to maintain SBP <160 mmHg. For SAH, administer the calcium channel blocker nimodipine to prevent vasospasm.
High-Priority Nursing ADPIE Actions
Airway & Aspiration: Keep the patient NPO until a formal swallowing screen is completed within 24 hours to prevent aspiration pneumonia.
ICP Management: Elevate the head of bed 30°, keep head/neck in midline, and avoid hip flexion to maximize venous drainage and reduce intracranial pressure.
Safety & Pattern Recognition: Left-brain stroke causes right hemiplegia, aphasia, slow/cautious behavior, and depression. Right-brain stroke causes left hemiplegia, spatial-perceptual neglect, and highly impulsive, safety-compromising behavior. Protect from injury and address one-sided neglect.
VTE Prophylaxis: Implement passive/active range of motion, sequential compression devices, and low-molecular-weight heparin.
CC | PRIMER ICP
12 Aug 2026
00:25:15
Intracranial Regulation & Monro-Kellie Doctrine The skull contains brain tissue (78%), blood (12%), and CSF (10%). Under Monro-Kellie, because this volume is constant, an increase in any one component must be offset by displacing another; otherwise, intracranial pressure (ICP) rises. Compensations include displacing CSF, collapsing cerebral veins, and compressing tissue. Decompensation causes ischemia. Normal ICP is 5 to 15 mm Hg; sustained pressure >20 mm Hg is abnormal.
Cerebral Perfusion Pressure (CPP) & Blood Flow CBF requires constant O2 and glucose. Autoregulation maintains constant CBF when MAP is between 70 and 150 mm Hg. CPP = MAP - ICP. Normal CPP is 60 to 100 mm Hg; <50 mm Hg causes ischemia and neuron death, while <30 mm Hg is incompatible with life. Hypercapnia (high PaCO2) and acidosis dilate cerebral vessels, increasing CBF and ICP.
Pathophysiology of Worsening ICP Insult triggers edema, compressing ventricles and vessels. This decreases CBF, causing hypoxia and brain cell death. The resulting acidosis and hypercapnia trigger vasodilation, raising blood volume and worsening ICP in a lethal feedback loop. Unrelieved pressure causes brainstem compression and downward herniation through the foramen magnum, causing respiratory arrest and death.
Assessment & Clinical Findings
LOC: The most sensitive indicator of neurologic status.
Cushing’s Triad: Systolic hypertension with widening pulse pressure, bradycardia, and irregular respirations—an emergency indicating impending herniation.
Ocular: Compression of CN III causes an ipsilateral fixed, dilated pupil, indicating herniation.
Motor: Rising ICP leads to decorticate flexion (cortical interruption) or decerebrate extension (midbrain/brainstem damage; arms stiff, hyperpronated).
CSF Leak: Rhinorrhea/otorrhea from basilar fractures poses a high meningitis risk. Confirm CSF via glucose testing or the halo sign (yellow ring around blood) on gauze.
Interventions & Management
Airway first: Intubate if GCS ≤ 8. Limit suction to <10s and 2 passes, pre-oxygenating with 100% O2.
Positioning: Elevate HOB to 30 degrees midline to promote venous drainage, avoiding extreme hip/neck flexion.
Osmotherapy: Give IV Mannitol (25%) or Hypertonic Saline to shift fluid from cells into vessels. Monitor sodium and osmolality.
Diagnostics: Head CT is the gold standard. Lumbar puncture is contraindicated due to herniation risk.
Ventriculostomy: Gold standard for monitoring ICP. Level the transducer with the tragus of the ear. If P2 wave is higher than P1, compliance is compromised.
CC | ICP
12 Aug 2026
01:03:08
Intracranial Regulation & Monro-Kellie Doctrine The skull contains brain tissue (78%), blood (12%), and CSF (10%). Under Monro-Kellie, because this volume is constant, an increase in any one component must be offset by displacing another; otherwise, intracranial pressure (ICP) rises. Compensations include displacing CSF, collapsing cerebral veins, and compressing tissue. Decompensation causes ischemia. Normal ICP is 5 to 15 mm Hg; sustained pressure >20 mm Hg is abnormal.
Cerebral Perfusion Pressure (CPP) & Blood Flow CBF requires constant O2 and glucose. Autoregulation maintains constant CBF when MAP is between 70 and 150 mm Hg. CPP = MAP - ICP. Normal CPP is 60 to 100 mm Hg; <50 mm Hg causes ischemia and neuron death, while <30 mm Hg is incompatible with life. Hypercapnia (high PaCO2) and acidosis dilate cerebral vessels, increasing CBF and ICP.
Pathophysiology of Worsening ICP Insult triggers edema, compressing ventricles and vessels. This decreases CBF, causing hypoxia and brain cell death. The resulting acidosis and hypercapnia trigger vasodilation, raising blood volume and worsening ICP in a lethal feedback loop. Unrelieved pressure causes brainstem compression and downward herniation through the foramen magnum, causing respiratory arrest and death.
Assessment & Clinical Findings
LOC: The most sensitive indicator of neurologic status.
Cushing’s Triad: Systolic hypertension with widening pulse pressure, bradycardia, and irregular respirations—an emergency indicating impending herniation.
Ocular: Compression of CN III causes an ipsilateral fixed, dilated pupil, indicating herniation.
Motor: Rising ICP leads to decorticate flexion (cortical interruption) or decerebrate extension (midbrain/brainstem damage; arms stiff, hyperpronated).
CSF Leak: Rhinorrhea/otorrhea from basilar fractures poses a high meningitis risk. Confirm CSF via glucose testing or the halo sign (yellow ring around blood) on gauze.
Interventions & Management
Airway first: Intubate if GCS ≤ 8. Limit suction to <10s and 2 passes, pre-oxygenating with 100% O2.
Positioning: Elevate HOB to 30 degrees midline to promote venous drainage, avoiding extreme hip/neck flexion.
Osmotherapy: Give IV Mannitol (25%) or Hypertonic Saline to shift fluid from cells into vessels. Monitor sodium and osmolality.
Diagnostics: Head CT is the gold standard. Lumbar puncture is contraindicated due to herniation risk.
Ventriculostomy: Gold standard for monitoring ICP. Level the transducer with the tragus of the ear. If P2 wave is higher than P1, compliance is compromised.
CC | PRIMER Neuro Assessment
12 Aug 2026
00:21:35
1. Structure & Cellular Biology
Organization: The CNS consists of the brain, spinal cord, and CN I-II. The PNS contains CN III-XII, spinal nerves, and the ANS.
Cells & Myelin: Neurons conduct action potentials via saltatory conduction across nodes of Ranvier, accelerated by myelin. Astrocytes form the blood-brain barrier and create scar tissue (gliosis) upon injury. Oligodendrocytes myelinate CNS axons; Schwann cells myelinate PNS axons.
Synapses: Neurotransmitters cross synapses to alter impulse transmission, using excitatory (glutamate) or inhibitory (GABA) pathways.
2. Pathways, Lobes & Perfusion
Tracts: Ascending tracts carry sensory input (spinothalamic for pain/temp; dorsal columns for touch, vibration, position). Descending tracts (corticospinal) carry motor output.
Motor Lesions: UMN lesions cause spasticity, hyperreflexia, and weakness. LMN lesions cause flaccidity, hyporeflexia, and muscle atrophy.
Perfusion: Anterior circulation stems from carotids; posterior from vertebral-basilar systems, joining at the circle of Willis.
3. Bedside Assessment
Mental Status: Ongoing check of consciousness, orientation, cognition, and mood/affect.
Cranial Nerves: CN III, IV, VI coordinate eye movements. Pupil non-constriction (CN III) is an early sign of brain herniation. Corneal reflex tests CN V/VII. Gag reflex tests CN IX/X; a weak gag risks aspiration. Midline tongue protrusion checks CN XII.
Sensory & Proprioception: Test touch, pain, vibration, and digit position. A positive Romberg test indicates posterior column dysfunction.
Reflexes: Deep tendon reflexes are graded 0–5. An extensor plantar response (toes up) signals an abnormal UMN lesion.
4. Diagnostics & Nursing Interventions
CSF Analysis: Normal CSF is clear/colorless, with pressure of 60–150 mm H2O, protein of 15–45 mg/dL, and glucose of 40–70 mg/dL.
Lumbar Puncture (LP) Care: LP is contraindicated in increased ICP due to risk of herniation. Pre-procedure, check coagulation and place the patient in a sitting/side-lying flexed position. Post-procedure, keep flat, monitor for headache, and push fluids.
Aging: Aging causes cerebral atrophy, wider ventricles, reduced blood flow, and demyelination. This leads to orthostatic hypotension, poor thermoregulation, and high fall risks.
CC | Neuro Assessment
12 Aug 2026
00:48:31
1. Structure & Cellular Biology
Organization: The CNS consists of the brain, spinal cord, and CN I-II. The PNS contains CN III-XII, spinal nerves, and the ANS.
Cells & Myelin: Neurons conduct action potentials via saltatory conduction across nodes of Ranvier, accelerated by myelin. Astrocytes form the blood-brain barrier and create scar tissue (gliosis) upon injury. Oligodendrocytes myelinate CNS axons; Schwann cells myelinate PNS axons.
Synapses: Neurotransmitters cross synapses to alter impulse transmission, using excitatory (glutamate) or inhibitory (GABA) pathways.
2. Pathways, Lobes & Perfusion
Tracts: Ascending tracts carry sensory input (spinothalamic for pain/temp; dorsal columns for touch, vibration, position). Descending tracts (corticospinal) carry motor output.
Motor Lesions: UMN lesions cause spasticity, hyperreflexia, and weakness. LMN lesions cause flaccidity, hyporeflexia, and muscle atrophy.
Perfusion: Anterior circulation stems from carotids; posterior from vertebral-basilar systems, joining at the circle of Willis.
3. Bedside Assessment
Mental Status: Ongoing check of consciousness, orientation, cognition, and mood/affect.
Cranial Nerves: CN III, IV, VI coordinate eye movements. Pupil non-constriction (CN III) is an early sign of brain herniation. Corneal reflex tests CN V/VII. Gag reflex tests CN IX/X; a weak gag risks aspiration. Midline tongue protrusion checks CN XII.
Sensory & Proprioception: Test touch, pain, vibration, and digit position. A positive Romberg test indicates posterior column dysfunction.
Reflexes: Deep tendon reflexes are graded 0–5. An extensor plantar response (toes up) signals an abnormal UMN lesion.
4. Diagnostics & Nursing Interventions
CSF Analysis: Normal CSF is clear/colorless, with pressure of 60–150 mm H2O, protein of 15–45 mg/dL, and glucose of 40–70 mg/dL.
Lumbar Puncture (LP) Care: LP is contraindicated in increased ICP due to risk of herniation. Pre-procedure, check coagulation and place the patient in a sitting/side-lying flexed position. Post-procedure, keep flat, monitor for headache, and push fluids.
Aging: Aging causes cerebral atrophy, wider ventricles, reduced blood flow, and demyelination. This leads to orthostatic hypotension, poor thermoregulation, and high fall risks.
CC | PRIMER CKD & AKI
12 Aug 2026
00:17:01
1. Pathophysiology
AKI: Sudden, potentially reversible decline in GFR.
Prerenal: Decreased perfusion (hypovolemia, shock, HF). Oliguria occurs without tissue damage; reversible with fluids.
Intrarenal: Direct tissue damage, 90% from Acute Tubular Necrosis (ATN) (ischemia, sepsis, nephrotoxins).
Diuretic (1–5+ L/d): Osmotic diuresis (high urea). Risk of hypovolemia, hypotension, hyponatremia, and hypokalemia.
Recovery: GFR increases, BUN/Creatinine stabilize (takes up to 12 months).
CKD Manifestations (Uremia):
Cardiovascular: Leading cause of death; due to vascular calcification, volume overload, and hypertension.
Hematologic: Anemia from decreased erythropoietin.
CKD-MBD: Low active Vitamin D reduces calcium absorption. Hypocalcemia triggers PTH release, causing bone demineralization (osteomalacia, osteitis fibrosa) and calcifications.
3. Diagnostics & Priority Interventions
Metrics: GFR is the best indicator of kidney function. Creatinine is the best AKI marker. Proteinuria is first sign of CKD.
Hyperkalemia Emergency Care:
Cardioprotection: IV Calcium Gluconate (stabilizes myocardium).
Shift K+ Intracellularly: IV Regular Insulin + Glucose, or IV Sodium Bicarbonate.
Definitive Removal: Hemodialysis or Kayexalate (avoid in paralytic ileus due to bowel necrosis).
Fluid Limits: Oliguric AKI: previous 24-hr loss + 600 mL.
Anemia: Exogenous EPO. Monitor for hypertension, clots; supplement iron.
4. RRT & Post-Op Care
HD: Rapid fluid/solute shifts. Assess AV Fistula for thrill and bruit. Safety: No BP/blood draws/IVs in access arm. Complication: Hypotension, cramps.
CRRT: Slow, continuous solute/fluid removal for hemodynamically unstable AKI.
Transplantation: Post-op priority is fluid/electrolyte balance. Watch for massive diuresis (replace mL-for-mL) or ATN. CVD is the leading cause of death post-transplant.
CC | CKD & AKI (GU)
12 Aug 2026
00:56:55
1. Pathophysiology
AKI: Sudden, potentially reversible decline in GFR.
Prerenal: Decreased perfusion (hypovolemia, shock, HF). Oliguria occurs without tissue damage; reversible with fluids.
Intrarenal: Direct tissue damage, 90% from Acute Tubular Necrosis (ATN) (ischemia, sepsis, nephrotoxins).
Diuretic (1–5+ L/d): Osmotic diuresis (high urea). Risk of hypovolemia, hypotension, hyponatremia, and hypokalemia.
Recovery: GFR increases, BUN/Creatinine stabilize (takes up to 12 months).
CKD Manifestations (Uremia):
Cardiovascular: Leading cause of death; due to vascular calcification, volume overload, and hypertension.
Hematologic: Anemia from decreased erythropoietin.
CKD-MBD: Low active Vitamin D reduces calcium absorption. Hypocalcemia triggers PTH release, causing bone demineralization (osteomalacia, osteitis fibrosa) and calcifications.
3. Diagnostics & Priority Interventions
Metrics: GFR is the best indicator of kidney function. Creatinine is the best AKI marker. Proteinuria is first sign of CKD.
Hyperkalemia Emergency Care:
Cardioprotection: IV Calcium Gluconate (stabilizes myocardium).
Shift K+ Intracellularly: IV Regular Insulin + Glucose, or IV Sodium Bicarbonate.
Definitive Removal: Hemodialysis or Kayexalate (avoid in paralytic ileus due to bowel necrosis).
Fluid Limits: Oliguric AKI: previous 24-hr loss + 600 mL.
Anemia: Exogenous EPO. Monitor for hypertension, clots; supplement iron.
4. RRT & Post-Op Care
HD: Rapid fluid/solute shifts. Assess AV Fistula for thrill and bruit. Safety: No BP/blood draws/IVs in access arm. Complication: Hypotension, cramps.
CRRT: Slow, continuous solute/fluid removal for hemodynamically unstable AKI.
Transplantation: Post-op priority is fluid/electrolyte balance. Watch for massive diuresis (replace mL-for-mL) or ATN. CVD is the leading cause of death post-transplant.
Fatigue: Secondary to tissue hypoxia (anemia, cancer).
Infection Risk: Compromised immunity and risk for infection is a major concern in hematologic cancers and a common side effect of therapy.
Pain: Common and classic in sickle cell disease (SCD) and oncology.
Perfusion & Clotting: Excessive clotting impairs perfusion; inadequate clotting causes blood loss and fluid volume deficit.
Anemia: Definition & Pathophysiology Anemia is not a disease but a manifestation of an underlying pathologic process. It is defined as a deficit in red blood cell (RBC) count, hemoglobin (Hgb) quantity/quality, and/or volume of packed red blood cells (hematocrit). Tissue hypoxia drives all clinical findings. The body compensates via cardiopulmonary escalation, increasing heart rate (HR) and stroke volume to maintain cardiac output (CO). Low blood viscosity contributes to systolic murmurs and bruits. If O2 demand exceeds supply, angina or MI occurs. Chronic overwork leads to heart failure (HF), cardiomegaly, congestion, and peripheral edema.
Diagnostics & Classification Diagnostics rely on CBC, reticulocyte count, and peripheral smear. Anemia is classified by:
Morphology (RBC size/color): Most accurate framework.
Normocytic, Normochromic (MCV 80–95 fL, MCH 27–31 pg): Caused by acute blood loss, hemolysis, CKD, cancers, or SCD.
Microcytic, Hypochromic (MCV <80 fL, MCH <27 pg): Caused by iron deficiency, thalassemia, lead poisoning, B6/copper deficiency.
Macrocytic, Normochromic (MCV >95 fL, MCH >31 pg): Caused by B12 (cobalamin) deficiency, folic acid deficiency, or liver disease.
Etiology (Cause): Best for structuring care. Divided into decreased RBC production, blood loss, or increased RBC destruction (hereditary like SCD/G6PD vs. acquired like DIC, HELLP, prosthetic valves, or bypass).
Severity & Clinical Manifestations Symptoms depend on onset speed, severity, and Hgb level:
Mild (Hgb 10–12 g/dL): Often asymptomatic. Heavy exercise triggers compensatory palpitations, mild fatigue, and dyspnea.
Moderate (Hgb 6–10 g/dL): Cardiopulmonary symptoms (dyspnea, palpitations) occur both during activity and at rest.
Severe (Hgb <6 g/dL): Multi-system decompensation occurs.
Integumentary: Pallor (shunted blood flow), jaundice (bilirubin from RBC hemolysis), and severe itching (accumulation of skin bile).
Cardiopulmonary: Marked tachycardia, angina, murmurs, and congestive failure.
CC | GU
12 Aug 2026
00:54:30
1. Anatomy & Blood Supply The upper urinary tract has two retroperitoneal, bean-shaped kidneys (T12–L3) and 2 ureters. The lower tract comprises the bladder and urethra. Each kidney is shielded by a fibrous capsule and cushioned by fat. The functional unit is the nephron (~1 million), consisting of a glomerulus, Bowman's capsule, and tubule system (PCT, loop of Henle, DCT, and collecting ducts). Blood flow is ~1200 mL/min (20-25% of cardiac output) via the renal artery, which divides into afferent arterioles.
2. Physiology of Urine Formation Urine is formed through filtration, reabsorption, secretion, and excretion.
Glomerular Filtration: Hydrostatic pressure filters blood across a porous, semipermeable membrane into Bowman’s capsule, yielding a filtrate lacking cells and large proteins. Normal Glomerular Filtration Rate (GFR) is ~125 mL/min; only ~1 mL/min is excreted as urine.
Tubular Function:
PCT: Reabsorbs 80% of electrolytes and water, all glucose, amino acids, and bicarbonate; secretes H+ and creatinine.
Loop of Henle: Conserves water and concentrates filtrate. Descending loop is water-permeable; ascending limb actively reabsorbs Cl- and Na+ (25% of sodium load) and is water-impermeable.
DCT & Collecting Ducts: Finalize regulation of water (controlled by ADH, which increases permeability) and acid-base balance (reabsorbing HCO3- and secreting H+). Aldosterone promotes Na+ and water reabsorption in exchange for K+ excretion. Atrial Natriuretic Peptide (ANP) opposes this by increasing Na+ excretion and GFR.
3. Hormonal & Regulatory Functions
Erythropoietin: Released during hypoxia or hypoperfusion, stimulating RBC production (deficient in renal failure, causing anemia).
RAAS: Juxtaglomerular cells release renin during hypoperfusion, low BP, or hyponatremia. Renin converts angiotensinogen to angiotensin I, which ACE converts to angiotensin II—causing vasoconstriction and aldosterone release.
Prostaglandins (PGE2, PGI2): Medullary vasodilators that maintain renal blood flow and counteract vasoconstrictors.
Vitamin D: Kidneys perform the final activation step of vitamin D, essential for calcium absorption.
4. Diagnostics & Assessment
Key Labs: Serum creatinine is the most reliable renal function index (released at a constant rate from muscle). Creatinine clearance (24-hr urine) approximates GFR. BUN rises with dysfunction but is altered by protein intake, tissue breakdown, and hydration.
Physical Exam: Involves palpation of the right kidney and indirect fist percussion of the costovertebral angle (CVA) to elicit pain in infection or obstruction.
Nephrotoxic Risks: Drugs like aminoglycosides, NSAIDs, and contrast media are highly nephrotoxic. Dehydration increases the risk of contrast-induced nephropathy.
Nutrition: Start trophic enteral nutrition (10 mL/hr) within 24h to protect gut mucosa.
CC | Dysrhythmia
12 Aug 2026
00:43:28
ell Properties & Conduction** Heart cells have four properties: automaticity, excitability, conductivity, contractility [1, 2]. Conduction travels from the SA node (60–100 bpm) through the AV node (40–60 bpm), bundle of His, bundle branches, to Purkinje fibers (20–40 bpm) [1, 3]. Vagal tone slows heart rate (HR); sympathetic activity increases HR and contractility [1]. Resting potential features high internal K+, external Na+; depolarization (Phase 0) is rapid Na+ influx [1, 4]. ECG Basics & Waveforms Leads II and V1 are used for monitoring [2]. Grid: horizontally, small square = 0.04s, large = 0.20s; vertically, small = 0.1 mV, large = 0.5 mV [5]. * P Wave (0.06–0.12s): Atrial depolarization [6]. * PR Interval (0.12–0.20s): Atrial-ventricular conduction [6]. * QRS Complex (<0.12s): Ventricular depolarization; pathologic Q (>=0.03s) suggests MI [6]. * ST Segment (0.12s): Isoelectric line; elevation or depression indicates ischemia or MI [6]. * T Wave (0.16s): Ventricular repolarization [6]. * QT Interval (0.34–0.43s): Total ventricular depolarization/repolarization [6]. Dysrhythmias & Treatment * Sinus Bradycardia (<60 bpm): Regular. Symptomatic bradycardia is treated with atropine, transcutaneous pacing (TCP), or dopamine/epinephrine [7, 8]. * Sinus Tachycardia (101–180 bpm): Due to stress, fever, pain; treat the cause [8, 9]. * PSVT (151–220 bpm): Reentrant. Vagal maneuvers, rapid IV adenosine (causes brief asystole), BBs, CCBs, or cardioversion [8, 10]. * Atrial Flutter: Sawtooth F-waves (200–350 bpm). Rate controllers, cardioversion, or catheter ablation [8, 11]. * Atrial Fibrillation: Chaotic f-waves (350–600 bpm); irregular. Lost atrial kick drops CO; stasis risks thrombi/stroke [11, 12]. Rate control: metoprolol, diltiazem, digoxin. Stroke prevention: warfarin, apixaban [12]. * AV Blocks: 1st-degree: constant PR >0.20s [8, 13]. Type I (Wenckebach): progressive PR lengthening until QRS drops [8, 13]. Type II (Mobitz II): constant PR, random dropped QRS; requires pacemaker [8, 14]. 3rd-degree (complete): complete AV dissociation; needs TCP, dopamine/epinephrine, pacemaker [8, 14]. * PVCs: Early, wide (>0.12s) distorted QRS. R-on-T can trigger lethal VT/VF [14, 15]. * VT (150–250 bpm): Stable VT uses amiodarone/procainamide; pulseless VT needs CPR/defibrillation [15, 16]. * VF: Chaotic quivering; zero CO. Lethal. Needs CPR, rapid defibrillation, epinephrine, amiodarone [16-18]. * Asystole / PEA: No pulse. Needs CPR, epinephrine, and intubation [18]. Key Interventions * Defibrillation: Unsynchronized shock (Biphasic 120–200J, Monophasic 360J) for VF/pulseless VT [17, 19]. * Cardioversion: Synchronized shock on R-wave for unstable tachycardias [20, 21]. * Pacemakers: Demand pacing. Malfunctions: failure to sense (inappropriate firing), capture (no contraction), or pace (no spike) [22, 23]. Limit arm activity post-insertion to avoid lead displacement [24].
This summary encapsulates the core cellular mechanisms, normal electrocardiographic intervals, critical dysrhythmia features, and emergency clinical protocols directly from your study materials.
📚 I can compile these key dysrhythmias and emergency actions into an interactive practice quiz to help test your bedside decision-making and pattern-recognition skills.
CC | Dysrhythmia
12 Aug 2026
01:11:08
Cell Properties & Conduction** Heart cells have four properties: automaticity, excitability, conductivity, contractility [1, 2]. Conduction travels from the SA node (60–100 bpm) through the AV node (40–60 bpm), bundle of His, bundle branches, to Purkinje fibers (20–40 bpm) [1, 3]. Vagal tone slows heart rate (HR); sympathetic activity increases HR and contractility [1]. Resting potential features high internal K+, external Na+; depolarization (Phase 0) is rapid Na+ influx [1, 4].
ECG Basics & Waveforms Leads II and V1 are used for monitoring [2]. Grid: horizontally, small square = 0.04s, large = 0.20s; vertically, small = 0.1 mV, large = 0.5 mV [5].
* Cardioversion: Synchronized shock on R-wave for unstable tachycardias [20, 21]. *
Pacemakers: Demand pacing. Malfunctions: failure to sense (inappropriate firing), capture (no contraction), or pace (no spike) [22, 23]. Limit arm activity post-insertion to avoid lead displacement [24].
POD | Welcome to the Podcast
11 Aug 2026
00:19:04
Season 1 = Health Assessment
Season 2 = Med\Surg
Season 3 = Pharmacology
Season 4 = Pediatrics
Season 5 = Mom\ Baby
Season 6 = Mental Health
Season 7 = Critical Care
Season 19 = ACLS Certification
Season 20 = PALS Certification
Season 30 = ATLS Certification (Trauma Certification for MDs)
CC | PRIMER CAD/ ACS
11 Aug 2026
00:21:43
Atherosclerosis is the foundational pathology of coronary artery disease (CAD). It is a progressive inflammatory disease characterized by lipid deposition within the intima of the arterial wall, triggered by chronic endothelial injury from factors like tobacco smoking, hypertension, hyperlipidemia, and diabetes. The disease progresses through three key developmental stages over several decades:
Fatty Streak: The earliest lesions, consisting of lipid-filled smooth muscle cells that appear yellow, starting in coronary arteries by age 20.
Fibrous Plaque: Appearing by age 30, lipoproteins transport lipids into the intima, where collagen covers them to form a grayish-white plaque. This narrows the vessel lumen and reduces distal blood flow.
Complicated Lesion: The most dangerous stage. Continued inflammation leads to plaque instability and rupture. This triggers massive platelet aggregation and thrombus formation on the exposed arterial wall, which can cause partial or total vessel occlusion.
Collateral circulation—arterial anastomoses that bypass blockages—can develop in response to chronic, slow-developing ischemia, allowing the heart to receive adequate oxygen. However, with acute coronary occlusion or severe spasms, collateral vessels lack the time to develop, resulting in severe ischemia or myocardial infarction (MI).
The 80/20 Core of CAD: Risk Factors and Clinical Variations
CAD is driven by a combination of nonmodifiable and major, modifiable risk factors:
Lipid Profiles: High low-density lipoprotein (LDL > 130 mg/dL) and total cholesterol (>200 mg/dL) accelerate plaque formation, whereas high-density lipoprotein (HDL, often called 'good cholesterol') protects arteries by transporting lipids back to the liver.
Hypertension & Diabetes: Shearing stress from high blood pressure (>120/80 mm Hg) directly injures the endothelium. Diabetes increases CAD risk two to four times by altering lipid metabolism and promoting endothelial dysfunction.
Tobacco & Lifestyle: Nicotine triggers catecholamine release (increasing heart rate and blood pressure), while carbon monoxide injures the endothelium and reduces oxygen transport. Physical inactivity and obesity further exacerbate these risks.
Demographic & Sex Disparities: CAD risk increases for men over 45 and women over 55. Men typically present with typical MI symptoms and have larger coronary arteries. Women experience onset about 10 years later (partly due to loss of estrogen's cardioprotective effects post-menopause), more often present with atypical symptoms like fatigue or shortness of breath, and suffer from higher post-MI mortality and undertreatment. Genetics contribute 40% to 60% of CAD risk, primarily influencing lipid metabolism.
CC | PRIMER Heart Failure
11 Aug 2026
00:23:00
1. Core Typology & Risk Factors
HFrEF (Systolic): EF < 40%. LV is dilated/hypertrophied, unable to eject blood effectively, reducing CO.
HFpEF (Diastolic): EF ≥ 50%. LV is stiff, noncompliant, causing high filling pressures and decreased filling volume.
Causes: HTN and CAD are primary. Long-term HTN control reduces HF incidence by 50%.
2. Pathophysiology: The Compensation Trap
Trigger: Myocardial injury -> decreased CO.
Cascade:
RAAS: Renal hypoperfusion triggers renin release, converting angiotensinogen to Angiotensin I, then Angiotensin II (vasoconstrictor). This stimulates water/sodium retention (via aldosterone/ADH) and myocardial fibrosis.
SNS: Baroreceptors sense low BP, releasing catecholamines to increase HR and contractility, raising myocardial O2 demand.
Remodeling: Chronic SNS/RAAS activation forces ventricular dilation/hypertrophy, making the heart more spherical and less effective, further declining LVEF.
Counter-Regulation: Natriuretic peptides (ANP/BNP) promote vasodilation and diuresis, opposing RAAS/SNS.
3. Left vs. Right HF
Left-Sided (Pulmonary Congestion): LV failure backs fluid into the left atrium/pulmonary bed. Signs: Dyspnea, orthopnea, paroxysmal nocturnal dyspnea (PND), bilateral crackles, displaced PMI, and pink, frothy sputum.
Right-Sided (Systemic Congestion): RV failure backs fluid into systemic veins. Signs: JVD, peripheral pitting edema, abdominal ascites, and hepatomegaly. Left HF is the primary cause of Right HF.
4. ADHF & Diagnostics
Profiles: Congestion (Wet/Dry) and perfusion (Warm/Cold). Wet-Warm (congested but perfused) is most common. Wet-Cold (fluid overload + hypoperfusion: cool extremities, low urine output, altered mentation) is critical, risking cardiogenic shock.
Diagnostics: Echocardiogram is the gold standard for LVEF/structure. BNP/NT-proBNP levels correlate with LV failure severity and fluid retention.
5. Pharmacotherapy & Interventions
HFrEF Survival Drugs: ACEi/ARBs/ARNIs (Sacubitril/Valsartan) and Beta-blockers (Metoprolol succinate, carvedilol) block neurohormonal activation and reverse remodeling. Aldosterone antagonists (spironolactone) and SGLT-2 inhibitors (dapagliflozin) reduce mortality.
Nursing Priorities: High-Fowler's position reduces venous return. Monitor daily weights (same scale/clothes before breakfast); notify provider of weight gain >3 lbs in 2 days or 5 lbs in a week.
CC | PRIMER HTN
11 Aug 2026
00:22:38
Hemodynamic Pathophysiology: Blood pressure (BP) is determined by cardiac output (CO) multiplied by systemic vascular resistance (SVR). Hypertension occurs when regulatory mechanisms (sympathetic nervous, vascular endothelium, renal, and endocrine) fail. The hallmark is persistently increased SVR, leading to vessel remodeling, atherosclerosis, and ischemia.
Diagnostic Classification: Based on two or more accurate readings on separate occasions, BP is categorized as:
Normal: <120 SBP and <80 DBP mmHg
Elevated: 120–129 SBP and <80 DBP mmHg
Stage 1: 130–139 SBP or 80–89 DBP mmHg
Stage 2: >=140 SBP or >=90 DBP mmHg
Target Organ Damage: Often asymptomatic ("silent killer") until severe. Complications include cardiovascular(LVH, CAD, heart failure), cerebrovascular (stroke, encephalopathy), renal (nephrosclerosis, CKD), retinal (vision loss), and peripheral vascular disease.
Hypertensive Crisis: Occurs at SBP >180 and/or DBP >120 mmHg.
Hypertensive Emergency: Active target organ damage exists. Requires immediate hospitalization and IV drug titration (e.g., sodium nitroprusside). The goal is to reduce Mean Arterial Pressure (MAP) by 20% to 25% to prevent ischemia.
Hypertensive Urgency: No active target organ damage; managed with oral drugs (e.g., captopril, labetalol, clonidine).
High-Yield Clinical Management & Interventions
First-Line Pharmacotherapy: Preferred agents for Stage 1 include thiazide diuretics, calcium channel blockers (CCBs), and ACE inhibitors or ARBs. Loop or potassium-sparing diuretics may also be utilized. Orthostatic hypotension and sexual dysfunction are common side effects that hinder adherence.
Actionable Lifestyle Modifications: Mandated for all elevated or hypertensive patients:
Diet & Sodium: Adopt the DASH diet; restrict sodium to <=2300 mg/day (ideally <=1500 mg/day).
Exercise & Weight: Minimum 150 minutes of moderate exercise per week. Weight loss reduces BP by 1 mmHg per kg lost.
Nursing Best Practices: Use correct cuff size (falsely high if too small). Assess for orthostatic changes (SBP drop >=20, DBP >=10, or HR increase >=20 bpm upon standing). Teach proper home BP monitoring (legs uncrossed, arm at heart level, rest 5 mins).
CC | PRIMER Cards Assessment
11 Aug 2026
00:20:58
1. Anatomy, Perfusion & Conduction
Layers & Chambers: Heart layers: endocardium, myocardium, epicardium. Pericardium contains 10-15 mL of fluid. LV is 2-3x thicker than RV to pump into systemic circulation.
Coronary Flow: Perfusion occurs primarily during diastole. LCA (branches into LAD, circumflex) supplies LV/LA/septum. RCA supplies RA/RV/posterior LV. In 90% of people, RCA supplies the AV node/bundle of His; blockages cause conduction defects.
Electrical System: SA Node → AV Node → Bundle of His → Bundle Branches → Purkinje fibers (impulse in 0.12s).
P wave: Atrial depolarization.
QRS: Ventricular depolarization.
T wave: Ventricular repolarization.
U wave: Purkinje repolarization; prominent in hypokalemia.
2. Hemodynamics & Autonomic Control
Metrics: CO=HR×SV (4-8 L/min). CI adjusts CO for BSA (2.8-4.2 L/min/m²).
Afterload: Force opposing ejection (SVR: 800-1200).
Contractility: Contraction force; increased by positive inotropes, decreased by ischemia/acidosis.
Perfusion: BP=CO×SVR. MAP=3SBP+2DBP; must be >60 mmHg to prevent vital organ ischemia.
Regulation: Sympathetic (β-adrenergic) increases HR/contractility; α1 receptors vasoconstrict. Parasympathetic (vagus) slows HR. Baroreceptors inhibit sympathetic tone under pressure overload, causing vasodilation and bradycardia.
3. Monitoring, Diagnostics & Care
Invasive Lines: Reference arterial lines to the phlebostatic axis (4th ICS, mid-chest). Too low produces falsely high BP; too high produces falsely low BP. Monitor distal extremity hourly for neurovascular compromise.
PA Catheter: Hypokalemia, hypomagnesemia, and hypoxia increase cardiac irritability, raising ventricular dysrhythmia risk during insertion.
Biomarkers:
Troponin (cTnT/cTnI): Choice for ACS; rises in 4-6 hrs, peaks 10-24 hrs, persists 10-14 days.
BNP / NT-pro-BNP: Distinguishes cardiac vs. respiratory causes of dyspnea.
Distribution: Water is 50%–60% of adult weight (varies with fat). ICF holds 2/3 of water; ECF holds 1/3 (interstitial fluid/plasma). Weight change is the best fluid shift indicator (1 kg = 1 L).
Capillary Exchange: Governed by hydrostatic (pushes out) and plasma oncotic (albumin pulls in) pressures. Edema occurs if hydrostatic pressure rises, oncotic falls, or lymphatics are blocked. Third-spacing traps nonfunctional fluid.
Regulatory Mechanisms
Hormones: Dehydration triggers thirst and pituitary ADH, raising renal water reabsorption. Aldosterone promotes sodium retention and potassium excretion. Atrial stretch releases natriuretic peptides (ANP/BNP) to excrete sodium/water.
Potassium (3.5–5.0 mEq/L): Dictates membrane potentials. Hyperkalemia (>5.0 mEq/L) causes peaked T waves, wide QRS, and arrest. Treatment: stop intake, diuretics/binders, shift K+ with insulin/beta-agonists, and stabilize heart with IV calcium. Hypokalemia (<3.5 mEq/L) causes flat T waves, U waves, and weakness. IV KCl must be diluted, infused slowly (<10 mEq/hr), and never pushed.
Divalent Cations: Calcium (9.0–10.5 mg/dL) is regulated by PTH and calcitonin. Hypercalcemia sedates nerves/muscles; hypocalcemia causes tetany with positive Chvostek/Trousseau signs. Magnesium (1.3–2.1 mEq/L) is vital for ATP. Hypomagnesemia (<1.3 mEq/L) resembles hypocalcemia, causing hyperactive reflexes and torsades.
Acid-Base Balance (pH 7.35–7.45)
Regulated by buffers, lung CO2 excretion, and renal bicarbonate/H+ control:
Respiratory Acidosis: Carbonic acid excess from hypoventilation (CO2 retention).
Respiratory Alkalosis: Carbonic acid deficit from hyperventilation (CO2 depletion).
Metabolic Acidosis: Bicarbonate deficit or acid buildup; anion gap is 8–12 mmol/L.
Metabolic Alkalosis: Bicarbonate excess or acid loss (vomiting/NG suction).
Crystalloid Solutions
Tonicity Effects:Hypotonic (e.g., 0.45% NaCl) dilutes ECF, swelling cells to treat hypernatremia. Isotonic (e.g., 0.9% NaCl, Lactated Ringer's) expands ECF volume without shifts. Hypertonic (e.g., 3.0% NaCl) draws water out of cells to treat hyponatremia.
CC | PRIMER ARDS/ ARF
11 Aug 2026
00:25:57
Acute Respiratory Failure (ARF) and Acute Respiratory Distress Syndrome (ARDS) are critical pulmonary conditions where gas exchange is insufficient to support systemic organs.
The 80/20 Core: Pathophysiology & Clinical Care
1. Classification of ARF ARF is a symptom of inadequate lung function, categorized into two types:
Hypoxemic (Oxygenation Failure):PaO2<60 mm Hg on room air. The core defect is inadequate O2 exchange, caused by V/Q mismatch, shunt, diffusion impairment, or alveolar hypoventilation. Shunt is an extreme mismatch where alveoli fill with fluid, making O2 therapy alone ineffective.
Hypercapnic (Ventilatory Failure):PaCO2>50 mm Hg with pH<7.35. It represents insufficient CO2 removal. Primary causes include CNS depression, neuromuscular disease, chest wall abnormalities, or airway obstruction (COPD, severe asthma).
2. ARDS Pathophysiology & Phases ARDS is a progressive form of ARF triggered by direct or indirect lung injury. Its hallmark is refractory hypoxemia—unresponsive to supplemental oxygen. It progresses in three phases:
Injury/Exudative (24–72 hours): Inflammatory mediators damage the membrane, causing edema. Alveolar type II cells are damaged, reducing surfactant, which causes collapse (atelectasis) and stiff lungs.
Reparative/Proliferative (1–2 weeks): Fibroblasts and inflammatory cells infiltrate, increasing resistance, causing pulmonary hypertension and decreased compliance.
Fibrotic/Late Phase: Diffuse scarring and remodeling further reduce gas exchange surface area, correlating with a poor prognosis.
3. Interprofessional Management Treatment focuses on treating causes, optimizing gas exchange, and avoiding complications:
Ventilation Support: BiPAP decreases the work of breathing (WOB) in mild ARF. Severe ARDS requires low tidal volume (VT) ventilation (4–8 mL/kg) to prevent barotrauma/volutrauma. This causes permissive hypercapnia (allowing PaCO2 up to 60 mm Hg if pH≥7.30). High PEEP is applied to recruit collapsed alveoli.
Prone Positioning: For severe ARDS with refractory hypoxemia; turning patients prone recruits dorsal alveoli, improving V/Q matching.
Supportive Care: Corticosteroids reduce airway inflammation. Fluid management keeps patients "on the dry side" to minimize pulmonary edema. Enteral nutrition should begin within 24–48 hours to preserve respiratory muscle mass.
Pneumonia: Acute lung parenchymal infection where pathogens invade via aspiration, inhalation, or blood. Inflammation increases vascular permeability, causing capillary leakage and alveolar fluid consolidation, impairing gas exchange. Clinical Rule: Initiate empiric antibiotic therapy immediately upon suspicion to reduce mortality; adjust only after culture results. Prevent aspiration pneumonia by elevating the head of the bed to ≥30° and checking the gag reflexes.
Tuberculosis (TB): Airborne disease caused by M. tuberculosis. LTBI vs. Active TB: Latent TB (LTBI) is asymptomatic, non-infectious, has normal chest x-rays, and requires single-drug therapy (e.g., isoniazid). Active TB is infectious, symptomatic, and treated with a 4-drug regimen (isoniazid, rifampin, pyrazinamide, ethambutol). Clinical Priority: Due to the rise of multidrug-resistant strains (MDR-TB), Directly Observed Therapy (DOT) is the standard of care for non-adherent patients.
2. Acute Pleural & Trauma Emergencies
Tension Pneumothorax: A life-threatening emergency where air enters the pleural space on inspiration but cannot escape, causing positive pressure, lung collapse, and mediastinal shift that compresses the heart and unaffected lung. Manifestations: Severe dyspnea, tachycardia, and tracheal deviation. Requires immediate needle decompression and chest tube insertion.
Flail Chest: Fracture of ≥3 consecutive ribs in ≥2 places, causing paradoxical chest wall movement (moves inward during inspiration, outward during expiration). Treat with oxygen, analgesics, and positive pressure ventilation to stabilize the segment.
Pathophysiology: Blockage of pulmonary arteries by a thrombus (usually from lower-limb DVT), obstructing alveolar perfusion.
Diagnosis & Management: Dyspnea is the most common symptom. A spiral CT scan is the gold standard for diagnosis (or V/Q scan if contrast is contraindicated). Key Care: Administer immediate anticoagulation (LMWH or IV heparin) to prevent clot extension; long-term therapy (e.g., warfarin) continues for ≥3 months.
4. Oncologic Malignancies: Lung Cancer
NSCLC vs. SCLC: Non-Small Cell (84%) grows moderately and is treated surgically if diagnosed in early stages (I–IIIA). Small Cell (SCLC, 13%) is highly aggressive, spreads early via blood and lymph (frequently to the brain), and is treated primarily with systemic chemotherapy and prophylactic cranial irradiation.
CC | PRIMER Obstructive Resp Complications
11 Aug 2026
00:25:15
1. Bronchiectasis: Mucus Stasis
Pathophysiology & Presentation: Inflammation destroys elastic and muscular wall structures, causing permanent dilation and impaired mucus clearance. It presents as a persistent cough with thick, purulent sputum. Massive hemoptysis is a life-threatening complication.
Care:CT scan is the gold standard. Care involves antibiotics (minimum 14 days), bronchodilators, and ACTs with hydration (2-3 L/day).
2. Cystic Fibrosis (CF): Ion Transport Defect
Pathophysiology & Presentation: An autosomal recessive CFTR mutation disrupts sodium and chloride transport, producing thick, dehydrated mucus that plugs respiratory, GI, and reproductive ducts. This causes progressive organ scarring, pancreatic insufficiency, and malabsorption.
Care:Sweat chloride testing is the gold standard. Management relies on aggressive ACTs and mucus-liquefying medications (dornase alfa), combined with pancreatic enzyme replacement before meals and mutation-specific CFTR modulators.
3. Asthma: Reversible Airflow Hyperreactivity
Pathophysiology & Presentation: Inflammation involves mast cells and eosinophils. Triggers cause an early IgE-mediated bronchospasm, often followed by a late-phase response 4-6 hours later. Signs include wheezing, dyspnea, and cough. A sudden absence of wheezing ("silent chest") is an emergency.
Care: Spirometry confirms reversibility (>12% and >200 mL FEV1 improvement post-bronchodilator). Inhaled corticosteroids (ICS) are first-line anti-inflammatories, often paired with LABAs. SABAs provide rescue relief, and patients follow an Asthma Action Plan based on peak flow zones.
4. COPD: Progressive Airflow Limitation
Pathophysiology & Presentation: Non-reversible airflow limitation is driven by chronic exposure to toxins, mainly smoking. Inflammation causes alveolar destruction (emphysema), goblet cell hyperplasia, and loss of elastic recoil. It presents with progressive exertional dyspnea, chronic cough, and a "barrel chest".
Care: Diagnosed when post-bronchodilator FEV1/FVC is <70%. Key care includes smoking cessation and stepwise inhaled drugs (LAMAs, LABAs, ICS). Calorie-dense nutrition combats cachexia, while pursed-lip breathing reduces air trapping.
CC | PRIMER Supporting Resp System
11 Aug 2026
00:27:19
I. Oxygen Therapy & Delivery Systems
Target: Maintain SpO2 >92% (or >88% in chronic COPD) or PaO2 >60 mmHg. Supplementing FiO2 >60% for >24 hours risks oxygen toxicity, causing severe pulmonary edema and inflammatory alveolar damage.
High-Flow Systems:Venturi Mask (delivers precise, fixed FiO2 for COPD), High-Flow Nasal Cannula (up to 60 L/min, 100% FiO2, heated humidification).
CO2 Narcosis: Some COPD patients lose sensitivity to high CO2, relying on a hypoxic drive to breathe. However, never withhold oxygen during severe, life-threatening hypoxemia.
II. Artificial Airways & Ventilation Modes
Airways:NPA (used in conscious or unconscious patients) vs. OPA (strictly unconscious patients to avoid vomiting/aspiration). Verify ET tube placement immediately via bilateral breath sounds, symmetric chest movement, and EtCO2 capnography; confirm via chest X-ray (2–3 cm above carina).
Cuff Management: Keep cuff pressure at 20–30 cm H2O to prevent aspiration and protect tracheal capillary perfusion.
Ventilation Modes:
AC (Assist-Control): Preset rate/VT. Spontaneous breaths get full VT; risks hyperventilation and respiratory alkalosis.
PC (Pressure Control): Preset pressure; VT varies. Prevents barotrauma in "stiff" or noncompliant lungs.
SIMV: Preset rate/VT; spontaneous breaths vary in volume.
PEEP: Splints open alveoli. High PEEP risks decreased venous return, preload, and cardiac output due to increased thoracic pressure.
III. Nursing Interventions & Complications
Suctioning: Only PRN (not routinely). Hyperoxygenate with 100% FiO2 before/after; limit passes to <10 seconds. Stop insertion when meeting resistance (carina) to avoid mucosal damage.
VAP Prevention: Elevate HOB 30–45 degrees, perform daily SAT/SBT trials, provide oral care with Chlorhexidine, and initiate early mobility.
Unplanned Extubation: Stay with the patient, call for help, and manually ventilate with BVM and 100% O2.
Accidental Decannulation (Trach <7 days): Spread stoma with hemostat, insert tube with obturator, then remove obturator; if impossible, cover stoma and use BVM over mouth/nose.
IV. Chest Tubes & Drainage Systems
Water-Seal Chamber: Shows tidaling (water rises on inspiration, falls on expiration). Cessation means lung re-expansion or tube occlusion. Continuous bubbling indicates an air leak.
Disconnection: Submerge the distal end in sterile water to re-establish a water seal. Never routinely clamp or strip chest tubes.
CC | PRIMER Assessment of the Resp System
11 Aug 2026
00:16:38
Gas Exchange: Primary goal: O2/CO2 exchange across alveolar-capillary membrane.
Anatomy: Upper tract warms/humidifies/filters air; epiglottis covers larynx to prevent aspiration. Carina is highly sensitive, triggering vigorous cough on stimulation.
Aspiration: Right mainstem bronchus is shorter, wider, straighter than left; aspiration is far more common in right lung.
Dead Space: Normal tidal volume (VT) is ~500 mL (~150 mL is anatomical dead space [VD] without gas exchange).
Alveoli & Surfactant: 300M+ alveoli connect via pores of Kohn. Surfactant lowers surface tension, preventing collapse (atelectasis).
Pleural Biology: Visceral pleura lacks pain fibers; parietal pleura has pain fibers, causing sharp pleuritic pain during inflammation.
Ventilation: Inspiration is active (diaphragm contracts, drawing air in); expiration is passive via elastic recoil.
Compliance & Resistance: Compliance decreases in edema, ARDS, fibrosis, and increases in COPD. Resistance is driven by airway diameter.
Control: Central chemoreceptors (medulla) respond to CSF pH/H+ changes; peripheral receptors respond to low PaO2, low pH, high PaCO2. COPD may rely on hypoxic drive.
Defense: Alveolar macrophages provide primary defense below bronchioles. Smoking impairs their phagocytic activity.
Gerontologic & Assessment Key Concepts
Aging: Stiffened chest walls, decreased muscle strength, and fewer elastic alveoli cause early airway closure in lung bases (lower PaO2). Decreased cilia, cough force, and pharyngeal sensation raise infection/aspiration risks.
Hypoxia Findings: Early signs: restlessness, apprehension, tachycardia, mild hypertension, tachypnea. Late signs: cyanosis, coma, hypotension, accessory muscle use.
Physical Exam:
Fremitus: High in pneumonia/edema (dense); low in COPD, pleural effusion.
Percussion: Normal resonance; hyperresonance in air trapping (COPD, pneumothorax); dullness in fluid/consolidation (effusion, pneumonia).
Oximetry: Arterial SpO2 (normal >95%) is inaccurate if <70%, or with cold, hypoperfusion, vasopressors. Venous SvO2/ScvO2 (normal 60-80%) tracks O2 supply/demand balance. Low values show anemia, low cardiac output, high demand. High values (sepsis) signal poor tissue extraction.
Procedures:
Bronchoscopy: Signed consent, NPO 6-12h before, keep NPO after until gag reflex returns.
Thoracentesis: Done sitting upright leaning on table; post-procedure chest X-ray checks for pneumothorax.
CC Pharm Milrinone
11 Aug 2026
00:36:08
Core Profile & MechanismMilrinone is a parenteral positive inotrope and vasodilator with selective phosphodiesterase III (PDE3) inhibitor activity. By preventing cyclic adenosine monophosphate (cAMP) breakdown in cardiac and vascular muscle cells, it increases myocardial contractility, causes vasodilation, and improves diastolic relaxation (lusitropy). This dual action reduces preload, afterload, and systemic vascular resistance with little to no chronotropic activity. Therapeutic effects occur at plasma levels of 100 to 300 ng/mL.
Primary Indications Milrinone is used for the short-term treatment of acute heart failure and other low cardiac output states like cardiogenic shock or post-cardiac surgery low cardiac output syndrome (LCOS). It can provide long-term palliative support in stage D heart failure patients awaiting transplant or mechanical circulatory support. Off-label uses include pediatric septic shock or postresuscitation stabilization, cerebral vasospasm after aneurysmal subarachnoid hemorrhage, and persistent pulmonary hypertension of the newborn (PPHN) with poor nitric oxide response.
Dosing & Administration
Adult HF Dosing: A 50 mcg/kg IV loading dose over 10–60 minutes (though heart failure guidelines do not recommend a bolus), followed by 0.125 to 0.75 mcg/kg/minute continuous infusion.
Renal Adjustments: Elimination is primarily renal (83% excreted unchanged in urine, half-life of 2.4 hours). For CrCl ≤ 50 mL/min, the adult continuous infusion rate must be adjusted down sequentially from 0.43 mcg/kg/min (CrCl 41–50) down to 0.2 mcg/kg/min (CrCl ≤ 5). Pediatric rates also require reductions for CrCl < 50 mL/min.
Administration Safety: Standard infusion is 200 mcg/mL, diluted in 0.45% or 0.9% NaCl or 5% Dextrose, run via a controlled device. It is not FDA-approved for intraosseous use, but the same doses can be given IO if IV access is unavailable.
Critical Safety & Adverse Reactions
Incompatibilities:Milrinone must never be co-administered with furosemide, as precipitation occurs immediately in the same line. It also cannot be given simultaneously with blood.
Arrhythmias & Monitoring:Continuous ECG monitoring is mandatory. Milrinone carries a substantial risk of serious ventricular arrhythmias (VT up to 12%, VF 0.2%), atrial flutter/fibrillation (up to 8%), supraventricular tachycardia, and premature ventricular contractions.
Hypotension & Other Risks: Hypotension occurs in 2.9% to 10.7% of patients. To reduce this risk, clinicians often avoid the loading dose in septic shock and neonatal PPHN. Thrombocytopenia is a delayed reaction occurring in up to 58% of patients.
CC | Coronary Artery Disease and ACS
11 Aug 2026
01:05:04
Atherosclerosis is the foundational pathology of coronary artery disease (CAD). It is a progressive inflammatory disease characterized by lipid deposition within the intima of the arterial wall, triggered by chronic endothelial injury from factors like tobacco smoking, hypertension, hyperlipidemia, and diabetes. The disease progresses through three key developmental stages over several decades:
Fatty Streak: The earliest lesions, consisting of lipid-filled smooth muscle cells that appear yellow, starting in coronary arteries by age 20.
Fibrous Plaque: Appearing by age 30, lipoproteins transport lipids into the intima, where collagen covers them to form a grayish-white plaque. This narrows the vessel lumen and reduces distal blood flow.
Complicated Lesion: The most dangerous stage. Continued inflammation leads to plaque instability and rupture. This triggers massive platelet aggregation and thrombus formation on the exposed arterial wall, which can cause partial or total vessel occlusion.
Collateral circulation—arterial anastomoses that bypass blockages—can develop in response to chronic, slow-developing ischemia, allowing the heart to receive adequate oxygen. However, with acute coronary occlusion or severe spasms, collateral vessels lack the time to develop, resulting in severe ischemia or myocardial infarction (MI).
The 80/20 Core of CAD: Risk Factors and Clinical Variations
CAD is driven by a combination of nonmodifiable and major, modifiable risk factors:
Lipid Profiles: High low-density lipoprotein (LDL > 130 mg/dL) and total cholesterol (>200 mg/dL) accelerate plaque formation, whereas high-density lipoprotein (HDL, often called 'good cholesterol') protects arteries by transporting lipids back to the liver.
Hypertension & Diabetes: Shearing stress from high blood pressure (>120/80 mm Hg) directly injures the endothelium. Diabetes increases CAD risk two to four times by altering lipid metabolism and promoting endothelial dysfunction.
Tobacco & Lifestyle: Nicotine triggers catecholamine release (increasing heart rate and blood pressure), while carbon monoxide injures the endothelium and reduces oxygen transport. Physical inactivity and obesity further exacerbate these risks.
Demographic & Sex Disparities: CAD risk increases for men over 45 and women over 55. Men typically present with typical MI symptoms and have larger coronary arteries. Women experience onset about 10 years later (partly due to loss of estrogen's cardioprotective effects post-menopause), more often present with atypical symptoms like fatigue or shortness of breath, and suffer from higher post-MI mortality and undertreatment. Genetics contribute 40% to 60% of CAD risk, primarily influencing lipid metabolism.
CC | Heart Failure
11 Aug 2026
01:04:04
1. Core Typology & Risk Factors
HFrEF (Systolic): EF < 40%. LV is dilated/hypertrophied, unable to eject blood effectively, reducing CO.
HFpEF (Diastolic): EF ≥ 50%. LV is stiff, noncompliant, causing high filling pressures and decreased filling volume.
Causes: HTN and CAD are primary. Long-term HTN control reduces HF incidence by 50%.
2. Pathophysiology: The Compensation Trap
Trigger: Myocardial injury -> decreased CO.
Cascade:
RAAS: Renal hypoperfusion triggers renin release, converting angiotensinogen to Angiotensin I, then Angiotensin II (vasoconstrictor). This stimulates water/sodium retention (via aldosterone/ADH) and myocardial fibrosis.
SNS: Baroreceptors sense low BP, releasing catecholamines to increase HR and contractility, raising myocardial O2 demand.
Remodeling: Chronic SNS/RAAS activation forces ventricular dilation/hypertrophy, making the heart more spherical and less effective, further declining LVEF.
Counter-Regulation: Natriuretic peptides (ANP/BNP) promote vasodilation and diuresis, opposing RAAS/SNS.
3. Left vs. Right HF
Left-Sided (Pulmonary Congestion): LV failure backs fluid into the left atrium/pulmonary bed. Signs: Dyspnea, orthopnea, paroxysmal nocturnal dyspnea (PND), bilateral crackles, displaced PMI, and pink, frothy sputum.
Right-Sided (Systemic Congestion): RV failure backs fluid into systemic veins. Signs: JVD, peripheral pitting edema, abdominal ascites, and hepatomegaly. Left HF is the primary cause of Right HF.
4. ADHF & Diagnostics
Profiles: Congestion (Wet/Dry) and perfusion (Warm/Cold). Wet-Warm (congested but perfused) is most common. Wet-Cold (fluid overload + hypoperfusion: cool extremities, low urine output, altered mentation) is critical, risking cardiogenic shock.
Diagnostics: Echocardiogram is the gold standard for LVEF/structure. BNP/NT-proBNP levels correlate with LV failure severity and fluid retention.
5. Pharmacotherapy & Interventions
HFrEF Survival Drugs: ACEi/ARBs/ARNIs (Sacubitril/Valsartan) and Beta-blockers (Metoprolol succinate, carvedilol) block neurohormonal activation and reverse remodeling. Aldosterone antagonists (spironolactone) and SGLT-2 inhibitors (dapagliflozin) reduce mortality.
Nursing Priorities: High-Fowler's position reduces venous return. Monitor daily weights (same scale/clothes before breakfast); notify provider of weight gain >3 lbs in 2 days or 5 lbs in a week.
CC | HTN
11 Aug 2026
00:59:51
Hemodynamic Pathophysiology: Blood pressure (BP) is determined by cardiac output (CO) multiplied by systemic vascular resistance (SVR). Hypertension occurs when regulatory mechanisms (sympathetic nervous, vascular endothelium, renal, and endocrine) fail. The hallmark is persistently increased SVR, leading to vessel remodeling, atherosclerosis, and ischemia.
Diagnostic Classification: Based on two or more accurate readings on separate occasions, BP is categorized as:
Normal: <120 SBP and <80 DBP mmHg
Elevated: 120–129 SBP and <80 DBP mmHg
Stage 1: 130–139 SBP or 80–89 DBP mmHg
Stage 2: >=140 SBP or >=90 DBP mmHg
Target Organ Damage: Often asymptomatic ("silent killer") until severe. Complications include cardiovascular (LVH, CAD, heart failure), cerebrovascular (stroke, encephalopathy), renal (nephrosclerosis, CKD), retinal (vision loss), and peripheral vascular disease.
Hypertensive Crisis: Occurs at SBP >180 and/or DBP >120 mmHg.
Hypertensive Emergency: Active target organ damage exists. Requires immediate hospitalization and IV drug titration (e.g., sodium nitroprusside). The goal is to reduce Mean Arterial Pressure (MAP) by 20% to 25% to prevent ischemia.
Hypertensive Urgency: No active target organ damage; managed with oral drugs (e.g., captopril, labetalol, clonidine).
High-Yield Clinical Management & Interventions
First-Line Pharmacotherapy: Preferred agents for Stage 1 include thiazide diuretics, calcium channel blockers (CCBs), and ACE inhibitors or ARBs. Loop or potassium-sparing diuretics may also be utilized. Orthostatic hypotension and sexual dysfunction are common side effects that hinder adherence.
Actionable Lifestyle Modifications: Mandated for all elevated or hypertensive patients:
Diet & Sodium: Adopt the DASH diet; restrict sodium to <=2300 mg/day (ideally <=1500 mg/day).
Exercise & Weight: Minimum 150 minutes of moderate exercise per week. Weight loss reduces BP by 1 mmHg per kg lost.
Nursing Best Practices: Use correct cuff size (falsely high if too small). Assess for orthostatic changes (SBP drop >=20, DBP >=10, or HR increase >=20 bpm upon standing). Teach proper home BP monitoring (legs uncrossed, arm at heart level, rest 5 mins).
CC | Cards Assessment
11 Aug 2026
00:48:31
1. Anatomy, Perfusion & Conduction
Layers & Chambers: Heart layers: endocardium, myocardium, epicardium. Pericardium contains 10-15 mL of fluid. LV is 2-3x thicker than RV to pump into systemic circulation.
Coronary Flow: Perfusion occurs primarily during diastole. LCA (branches into LAD, circumflex) supplies LV/LA/septum. RCA supplies RA/RV/posterior LV. In 90% of people, RCA supplies the AV node/bundle of His; blockages cause conduction defects.
Electrical System: SA Node → AV Node → Bundle of His → Bundle Branches → Purkinje fibers (impulse in 0.12s).
P wave: Atrial depolarization.
QRS: Ventricular depolarization.
T wave: Ventricular repolarization.
U wave: Purkinje repolarization; prominent in hypokalemia.
2. Hemodynamics & Autonomic Control
Metrics: CO=HR×SV (4-8 L/min). CI adjusts CO for BSA (2.8-4.2 L/min/m²).
Afterload: Force opposing ejection (SVR: 800-1200).
Contractility: Contraction force; increased by positive inotropes, decreased by ischemia/acidosis.
Perfusion: BP=CO×SVR. MAP=3SBP+2DBP; must be >60 mmHg to prevent vital organ ischemia.
Regulation: Sympathetic (β-adrenergic) increases HR/contractility; α1 receptors vasoconstrict. Parasympathetic (vagus) slows HR. Baroreceptors inhibit sympathetic tone under pressure overload, causing vasodilation and bradycardia.
3. Monitoring, Diagnostics & Care
Invasive Lines: Reference arterial lines to the phlebostatic axis (4th ICS, mid-chest). Too low produces falsely high BP; too high produces falsely low BP. Monitor distal extremity hourly for neurovascular compromise.
PA Catheter: Hypokalemia, hypomagnesemia, and hypoxia increase cardiac irritability, raising ventricular dysrhythmia risk during insertion.
Biomarkers:
Troponin (cTnT/cTnI): Choice for ACS; rises in 4-6 hrs, peaks 10-24 hrs, persists 10-14 days.
BNP / NT-pro-BNP: Distinguishes cardiac vs. respiratory causes of dyspnea.
Distribution: Water is 50%–60% of adult weight (varies with fat). ICF holds 2/3 of water; ECF holds 1/3 (interstitial fluid/plasma). Weight change is the best fluid shift indicator (1 kg = 1 L).
Capillary Exchange: Governed by hydrostatic (pushes out) and plasma oncotic (albumin pulls in) pressures. Edema occurs if hydrostatic pressure rises, oncotic falls, or lymphatics are blocked. Third-spacing traps nonfunctional fluid.
Regulatory Mechanisms
Hormones: Dehydration triggers thirst and pituitary ADH, raising renal water reabsorption. Aldosterone promotes sodium retention and potassium excretion. Atrial stretch releases natriuretic peptides (ANP/BNP) to excrete sodium/water.
Potassium (3.5–5.0 mEq/L): Dictates membrane potentials. Hyperkalemia (>5.0 mEq/L) causes peaked T waves, wide QRS, and arrest. Treatment: stop intake, diuretics/binders, shift K+ with insulin/beta-agonists, and stabilize heart with IV calcium. Hypokalemia (<3.5 mEq/L) causes flat T waves, U waves, and weakness. IV KCl must be diluted, infused slowly (<10 mEq/hr), and never pushed.
Divalent Cations: Calcium (9.0–10.5 mg/dL) is regulated by PTH and calcitonin. Hypercalcemia sedates nerves/muscles; hypocalcemia causes tetany with positive Chvostek/Trousseau signs. Magnesium (1.3–2.1 mEq/L) is vital for ATP. Hypomagnesemia (<1.3 mEq/L) resembles hypocalcemia, causing hyperactive reflexes and torsades.
Acid-Base Balance (pH 7.35–7.45)
Regulated by buffers, lung CO2 excretion, and renal bicarbonate/H+ control:
Respiratory Acidosis: Carbonic acid excess from hypoventilation (CO2 retention).
Respiratory Alkalosis: Carbonic acid deficit from hyperventilation (CO2 depletion).
Metabolic Acidosis: Bicarbonate deficit or acid buildup; anion gap is 8–12 mmol/L.
Metabolic Alkalosis: Bicarbonate excess or acid loss (vomiting/NG suction).
Crystalloid Solutions
Tonicity Effects:Hypotonic (e.g., 0.45% NaCl) dilutes ECF, swelling cells to treat hypernatremia. Isotonic (e.g., 0.9% NaCl, Lactated Ringer's) expands ECF volume without shifts. Hypertonic (e.g., 3.0% NaCl) draws water out of cells to treat hyponatremia.